<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/w/ProjectMundo-Anon-106A/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41598
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41598.2045-2322
   </journal-id>
   <journal-title-group>
    <journal-title>
     Scientific Reports
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Sci Rep
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2045-2322
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41598-023-45072-9
   </article-id>
   <article-id pub-id-type="manuscript">
    45072
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41598-023-45072-9
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/617
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/378/1689
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/378/340
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/378/3920
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/378/548
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/378/2587
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Matibabu ya Wagonjwa 95 wa Baada ya Covid kwa SSRIs
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes" id="Au1">
     <name name-style="western">
      <surname>
       Rus
      </surname>
      <given-names>
       Carla P.
      </given-names>
     </name>
     <address>
      <email>
       rusvries@ziggo.nl
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs41598023450729_cor1">
      a
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <name name-style="western">
      <surname>
       de Vries
      </surname>
      <given-names>
       Bert E. K.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       de Vries
      </surname>
      <given-names>
       Ingmar E. J.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Nutma
      </surname>
      <given-names>
       Idelette
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Kooij
      </surname>
      <given-names>
       J. J. Sandra
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Independent Researcher
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      The Hague
     </addr-line>
     <country country="NL">
      The Netherlands
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/016xsfp80
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.5590.9
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2293 1605
      </institution-id>
      <institution content-type="org-division">
       Donders Institute
      </institution>
      <institution content-type="org-name">
       Radboud University
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      6525 EN
     </addr-line>
     <addr-line content-type="city">
      Nijmegen
     </addr-line>
     <country country="NL">
      The Netherlands
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/05trd4x28
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.11696.39
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1937 0351
      </institution-id>
      <institution content-type="org-division">
       Centre for Mind/Brain Sciences (CIMeC)
      </institution>
      <institution content-type="org-name">
       University of Trento
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      38068
     </addr-line>
     <addr-line content-type="city">
      Rovereto
     </addr-line>
     <country country="IT">
      Italy
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution content-type="org-division">
       Department of Psychiatry
      </institution>
      <institution content-type="org-name">
       Amsterdam UMC/VUMC
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      1081 HJ
     </addr-line>
     <addr-line content-type="city">
      Amsterdam
     </addr-line>
     <country country="NL">
      The Netherlands
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/02axh0j46
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.491389.e
      </institution-id>
      <institution content-type="org-name">
       PsyQ
      </institution>
     </institution-wrap>
     <addr-line content-type="postcode">
      2593 HR
     </addr-line>
     <addr-line content-type="city">
      The Hague
     </addr-line>
     <country country="NL">
      The Netherlands
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs41598023450729_cor1">
     <label>
      a
     </label>
     <email>
      rusvries@ziggo.nl
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     2
    </day>
    <month>
     11
    </month>
    <year>
     2023
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2023
    </year>
   </pub-date>
   <volume>
    13
   </volume>
   <issue seq="18599">
    1
   </issue>
   <elocation-id>
    18599
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      15
     </day>
     <month>
      10
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      9
     </day>
     <month>
      7
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      15
     </day>
     <month>
      10
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      2
     </day>
     <month>
      11
     </month>
     <year>
      2023
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2023
    </copyright-statement>
    <copyright-year>
     2023
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Muhtasari
    </title>
    <p id="Par1">
     Baada ya maambukizi ya Covid-19, 12.5% wanapata dalili za baada ya Covid (PCS). Dalili zinaonyesha mifumo mingi ya viungo iliyoathirika. Baada ya mwaka mmoja, uchovu sugu, dysautonomia na malalamiko ya neva na ya kiakili yanatawala. Katika utafiti huu, wagonjwa 95 wa PCS walitibiwa kwa vizuizi vya kuchukua tena serotonin (SSRIs). Utafiti huu ulitumia dodoso la uchunguzi na kugundua kuwa theluthi mbili ya wagonjwa walikuwa na majibu mazuri hadi yenye nguvu kwa SSRIs, zaidi ya robo ya wagonjwa walikuwa na majibu ya wastani, wakati 10% waliripoti kutokuwa na majibu. Kwa ujumla, wagonjwa walipata kuboreshwa kwa ustawi kwa kiasi kikubwa. Ukungu wa ubongo na mzigo wa hisia ulipungua zaidi, ikifuatiwa na uchovu sugu na dysautonomia. Matokeo yalipimwa kwa vipimo vitatu tofauti ambavyo vilihusiana kwa nguvu na kila mmoja. Majibu kwa SSRIs katika hali za PCS yalielezewa na mifumo saba ya neurobiolojia inayowezekana kulingana na fasihi ya hivi karibuni juu ya PCS iliyounganishwa na maarifa yaliyopo tayari. Muhimu kwa kuelewa mifumo hii ni mwingiliano wa kibiokemia kati ya mifumo mbalimbali ya neurotransmitter na sehemu za mfumo wa kinga, na udhibiti wao usiofaa katika PCS. Kiungo kikuu kinaonekana kuwa na njia ya kimetaboliki ya kynurenine (KP) ambayo inashirikiana sana na mfumo wa kinga. KP hutumia mtangulizi sawa na serotonin: tryptophan. KP ni yenye shughuli nyingi katika PCS ambayo inadumisha uvimbe na ambayo husababisha ukosefu wa tryptophan. Hatimaye, njia zinazowezekana za utafiti wa baadaye ili kuendeleza mstari huu wa utafiti wa kliniki zinajadiliwa.
    </p>
   </abstract>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      18598
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      No
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      10
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      15
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41598_2023_Article_45072.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1">
   <title>
    Utangulizi
   </title>
   <p id="Par2">
    Post-Covid-syndrome (PCS) ni ugonjwa wa mifumo mingi wenye zaidi ya dalili 200 tofauti
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Kwa kuwa hali hii imetambuliwa kwa miaka mitatu tu, mengi bado hayajulikani na dalili mpya bado zinaibuka. Kuna zaidi ya wagonjwa milioni 100 wa PCS duniani kote. Takwimu hii inatokana na makadirio ya takwimu kutoka Uingereza
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Kutokana na ulemavu mkubwa unaohusishwa, PCS ni tatizo kubwa la kiafya lenye athari kubwa za kibinafsi, kijamii na kiuchumi. Athari za PCS kwa wagonjwa ni za kuvuruga: kwa afya yao ya kimwili na kiakili; kaya na familia, kulea watoto, kuchelewesha kupata watoto, shughuli za kijamii na burudani; elimu, kazi na kipato. Hii pia ina athari kubwa za kiuchumi. Bach alikadiria gharama ya kila mwaka ya dola bilioni 230 nchini Marekani, akidhani watu milioni 4 hawako kazini kutokana na PCS
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    .
   </p>
   <p id="Par3">
    Dalili kuu za PCS ni pamoja na: 'brainfog' (inayojumuisha 'fikra zenye ukungu', matatizo ya umakini na kumbukumbu), maumivu ya kichwa, mzigo wa hisia (kuongezeka kwa msisimko), uchovu mkali, upungufu wa pumzi, hali mbaya baada ya mazoezi (PEM), dysautonomia ikijumuisha postural orthostatic tachycardia syndrome (POTS), mapigo ya moyo yasiyo ya kawaida, usingizi uliovurugika, maumivu ya misuli, mast cell activation syndrome (MCAS), matatizo ya utumbo, kupungua kwa uwezo wa kunusa na tinnitus. Hizi kimsingi ni za asili ya neva na neuropsychiatric. Kwa wagonjwa wengi wa PCS, hakuna msingi wazi wa pathofiziolojia unaopatikana kwenye uchunguzi wa kawaida (damu). Hata hivyo, dysfunction ya mfumo wa neva inathibitishwa na mtihani wa meza ya mwinuko
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    . Hapa, mgonjwa aliye lala chali huinuliwa kwa pembe ya takriban 70%, huku mapigo ya moyo na shinikizo la damu vikifuatiliwa. Hivyo, POTS na dalili nyingine za dysautonomia zinaweza kugunduliwa. Neuropathy ya nyuzi ndogo pia wakati mwingine hupatikana
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Fasihi inaripoti sababu za PCS: neuroinflammation, kuongezeka kwa cytokines za pro-inflammatory, athari za kinga mwili, hypoxia kutokana na microclots, fibrin-amyloid microclots na uamsho wa virusi vya herpes kama vile Epstein-Barr virus
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Maeneo ya hypometabolic pia yanapatikana kwenye pons (sehemu ya shina la ubongo)
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Neva ya vagus pia hutoka kwenye pons. Neva hii ya fuvu inaweza kutofanya kazi vizuri katika PCS, na kusababisha dysautonomia
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Pons ni eneo la asili ya mfumo wa serotoninergic. Kutoka hapo, axons hutumwa kote kwenye CNS
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    .
   </p>
   <p id="Par5">
    Mapema, tulitambua kufanana kati ya dalili za PCS na ugonjwa wa uchovu sugu (ME/CFS)
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . ME/CFS inajulikana kuongeza cytokines za pro-inflammatory kwenye ubongo na kupunguza kazi ya mhimili wa hypothalamic–pituitary–adrenal (HPA) kwa muda
    <sup>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
    </sup>
    . Mhimili wa HPA hutoa glucocorticoids (GCs). GCs hufanya kazi kwenye karibu aina zote za seli za kinga na hufanya kazi za dhahiri za kupunguza kinga na kupunguza uchochezi
    <sup>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    . Kulingana na fasihi, inaonekana kwamba kwa wagonjwa wa PCS, kwa wastani, viwango vya cortisol hupimwa kuwa 50% ya kawaida
    <sup>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
    </sup>
    . Hii inaunga mkono dhana yetu kwamba mhimili wa HPA uliovurugika pia upo katika PCS.
   </p>
   <p id="Par6">
    Vizuizi vya kuchukua tena serotonin (SSRIs) vina angalau njia tatu za kuathiri mfumo wa kinga. Kwanza kwa kudhibiti mhimili wa HPA uliotajwa hapo awali
    <sup>
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
     ,
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     ,
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
    </sup>
    . Hufanya hivi kwa kuamsha mifumo ya neurotransmitter ya serotonin na norepinephrine. Neurotransmitters ni vitu vinavyotuma ishara kati ya seli za neva na seli za neva za ubongo (neurones)
    <sup>
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    . Ingawa SSRI kawaida huonyeshwa kwa unyogovu na matatizo ya wasiwasi, serotonin hupatikana katika sehemu nyingi za mwili: katika mfumo wa usagaji chakula, chembe za damu na kote kwenye mfumo mkuu wa neva (CNS)
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     ,
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
     <xref ref-type="bibr" rid="CR25">
      25
     </xref>
    </sup>
    . Hivyo SSRI ina athari kubwa mwilini. SSRI hufanya kuchukua tena serotonin na norepinephrine kwenye neuroni ya presynaptic kuwa jambo lisilowezekana, kuruhusu neurotransmitters hizi za ziada kwenye synapsi kupeleka ishara yao kwa neuroni ya postsynaptic kwa muda mrefu zaidi
    <sup>
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
     ,
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    .
   </p>
   <p id="Par7">
    Pili, SSRIs zinaweza kuathiri mfumo wa kinga kupitia mwingiliano na njia ya kynurenine (KP). KP ina jukumu la kuunda cofactor muhimu ya nishati: nicotinamide adenine dicleotide (NAD+). Kuna mwingiliano mkubwa kati ya KP na mfumo wa kinga
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
     ,
     <xref ref-type="bibr" rid="CR28">
      28
     </xref>
    </sup>
    . KP inafanya kazi kupita kiasi katika maambukizi mengi pamoja na PCS na inachangia kudumisha uvimbe. Njia zote za serotonin na KP zinatumia mtangulizi sawa tryptophan, amino asidi muhimu. Katika tukio la upungufu wa mtangulizi huyu, ambao ni hali iliyo na PCS, njia ya serotonin inayochochewa na SSRIs inaweza kuchukuliwa kama mshindani wa KP. (Tazama Fig. 6 katika sehemu “
    <xref ref-type="sec" rid="Sec25">
     Njia zinazowezekana za utendaji wa SSRIs
    </xref>
    ”)
    <sup>
     <xref ref-type="bibr" rid="CR26">
      26
     </xref>
     ,
     <xref ref-type="bibr" rid="CR29">
      29
     </xref>
     <xref ref-type="bibr" rid="CR27">
      27
     </xref>
     ,
     <xref ref-type="bibr" rid="CR28">
      28
     </xref>
     ,
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
     ,
     <xref ref-type="bibr" rid="CR31">
      31
     </xref>
     ,
     <xref ref-type="bibr" rid="CR32">
      32
     </xref>
    </sup>
    .
   </p>
   <p id="Par8">
    Tatu, baadhi ya SSRIs zina athari za ziada za kupunguza uvimbe, kama vile kuzuia sphingomyelinase acid (ASM) au ni agonisti wa kipokezi cha sigma1 kinachohusika katika kupunguza uzazi wa virusi na uanzishaji upya wa virusi vya herpes kama vile virusi vya Epstein-Barr
    <sup>
     <xref ref-type="bibr" rid="CR33">
      33
     </xref>
     <xref ref-type="bibr" rid="CR33">
      33
     </xref>
     ,
     <xref ref-type="bibr" rid="CR34">
      34
     </xref>
     ,
     <xref ref-type="bibr" rid="CR35">
      35
     </xref>
    </sup>
    . Agonisti ni kichocheo cha kipokezi, kinyume na antagonisti ambayo huzuia.
   </p>
   <p id="Par9">
    Kuhusu ushahidi wa kimaumbile:
    <bold>
     i
    </bold>
    katika mapitio ya majaribio 14 ya kliniki, tafiti 10 zilionyesha kuwa SSRI au kizuizi cha kuchukua tena serotonin na norepinephrine (SNRI) kilichopewa wakati wa maambukizi ya Covid-19 kilipunguza ukali wa maambukizi
    <sup>
     <xref ref-type="bibr" rid="CR36">
      36
     </xref>
    </sup>
    . Utafiti mwingine uligundua kuwa SSRI iliyotolewa wakati wa maambukizi ya Covid-19 inaweza kuzuia PCS
    <sup>
     <xref ref-type="bibr" rid="CR37">
      37
     </xref>
    </sup>
    . Muda wa matibabu na SSRI ulikuwa siku 10 hadi 14 tu katika tafiti hizi zote. Katika PCS iliyopo, utafiti mmoja tu unajulikana wa matibabu na SSRI, na unyogovu kama dalili
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
    </sup>
    . Katika utafiti huo wa wagonjwa 60, unyogovu ulipungua kwa 92%. Athari kwenye dalili za PCS hazikuripotiwa
    <sup>
     <xref ref-type="bibr" rid="CR38">
      38
     </xref>
    </sup>
    . Hadi sasa, hakuna uingiliaji wa dawa unaojulikana kuwa na ufanisi katika PCS, dawa zingine zinafanyiwa uchunguzi. Utafiti na SSRIs kwa sasa unakosekana. Hii ndiyo sababu mwandishi wa kwanza aliandika makala katika gazeti la Uholanzi NRC mnamo Desemba 17, 2020 akipendekeza kwamba SSRI inaweza kutumika katika matibabu ya PCS. Baada ya kuchapishwa, idadi inayoongezeka ya wagonjwa wa PCS waliripoti kutaka kujaribu matibabu na SSRI. Kwa kuzingatia ripoti za kushangaza za wagonjwa hao, kama vile: “Nimepata maisha yangu ya zamani tena”, tumeendelea kupendekeza kuzingatia SSRI katika PCS tangu wakati huo
    <sup>
     <xref ref-type="bibr" rid="CR39">
      39
     </xref>
    </sup>
    .
   </p>
   <p id="Par10">
    Kwa sababu ya umuhimu wa matibabu kwa kundi kubwa la wagonjwa wa PCS, tuliamua mwishoni mwa 2022 kuchunguza athari za matibabu na SSRI kwenye PCS.
   </p>
  </sec>
  <sec id="Sec2" sec-type="methods">
   <title>
    Mbinu
   </title>
   <sec id="Sec3">
    <title>
     Taarifa ya Maadili
    </title>
    <p id="Par11">
     Kamati ya Mapitio ya Maadili ya Matibabu ya Vituo vya Matibabu vya Chuo Kikuu cha Amsterdam imepitia utafiti, nambari 2023.0358. Kulingana na itifaki na nyaraka zilizowasilishwa, kamati inahitimisha kuwa muundo wa utafiti unakidhi mahitaji yanayotokana na sheria na kanuni zinazotumika, ikiwa ni pamoja na ECTR, MDR au IVDR, WGBO (Sheria ya Mkataba wa Matibabu) na AVG (Kanuni ya Jumla ya Ulinzi wa Data). Mbinu zote zilifanywa kwa mujibu wa miongozo na kanuni husika.
    </p>
    <p id="Par12">
     Kamati ya Mapitio ya Maadili ya Matibabu ya Vituo vya Matibabu vya Chuo Kikuu cha Amsterdam imesajiliwa na Ofisi ya Marekani ya Ulinzi wa Utafiti wa Binadamu (OHRP) kama IRB00013752. Nambari ya FWA iliyotolewa kwa Amsterdam UMC ni FWA00032965.
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     Matibabu
    </title>
    <p id="Par13">
     Wagonjwa ambao walikuwa na nia ya kutibiwa na SSRI na madaktari wao wa jumla (GP) walifahamishwa kwa barua pepe kuhusu asili ya majaribio ya matibabu, majibu yanayowezekana kwa SSRIs katika PCS, ni SSRIs gani zinaweza kutumika, kipimo, titration na athari zinazowezekana. Taarifa kwa wagonjwa na madaktari pia iliwekwa kwenye tovuti sepsis-en-daarna.nl/en/.
    </p>
    <p id="Par14">
     Hatukuwatibu wagonjwa wenyewe lakini tuliwashauri kushauriana na daktari wao (wa msingi) kuhusu matibabu na SSRI. Ilikuwa muhimu kila wakati kusisitiza kwamba SSRI katika PCS ilishauriwa kwa mifumo mingine ya kazi kuliko kwa dalili za unyogovu au wasiwasi. Kati ya SSRIs, agonists za kipokezi cha sigma1 kama fluvoxamine, citalopram, escitalopram na fluoxetine zilishauriwa kwa upendeleo. Hii ni kwa sababu dawa hizi zinaweza kupunguza cytokines za pro-inflammatory zilizoinuliwa
     <sup>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     . Tulipendekeza pia venlafaxine, ambayo si SSRI, bali ni SNRI. Kutoka kwa kipimo cha 150 mg kwa siku, pia hufanya kazi kupitia mfumo wa dopaminergic. Ilishauriwa kuanza na kipimo cha chini na kulingana na majibu na athari za pembeni, kuongeza kipimo kwa uangalifu, hadi kipimo kinachokubalika kilipofikiwa. Tulitumia kipimo cha unyogovu kama mwongozo. Ikiwa kulikuwa na athari nyingi za pembeni, tuliongeza SSRI polepole zaidi, kwa mfano, kuongeza tone la 2 mg citalopram kila wiki mbili. Vipimo vya mwisho vya SSRIs vilitofautiana. Baadhi ya wagonjwa walimaliza na 30 mg citalopram, wengine tu 5 mg. Tofauti hiyo pia ilikuwa kweli kwa SSRIs nyingine. Imebaki kazi ya kubinafsisha. Katika kesi ya athari mbaya za kudumu, tuliwashauri wagonjwa na madaktari wao kutumia SSRI nyingine, labda baada ya kuwa na wasifu wa pharmacogenetic kuundwa kwanza (Jedwali
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     ).
     <table-wrap id="Tab1">
      <label>
       Jedwali 1
      </label>
      <caption xml:lang="en">
       <p>
        Dozi za mwisho za aina mbalimbali za SSRIs katika mg.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left">
          <p>
           SSRI
          </p>
         </th>
         <th align="left">
          <p>
           Idadi ya wagonjwa (n = 95)
          </p>
         </th>
         <th align="left">
          <p>
           Dozi ya wastani
          </p>
         </th>
         <th align="left">
          <p>
           std
          </p>
         </th>
         <th align="left">
          <p>
           Dozi ya chini kabisa
          </p>
         </th>
         <th align="left">
          <p>
           Dozi ya juu kabisa
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           Citalopram
          </p>
         </td>
         <td align="left">
          <p>
           46
          </p>
         </td>
         <td align="left">
          <p>
           19.3
          </p>
         </td>
         <td align="left">
          <p>
           8.4
          </p>
         </td>
         <td align="left">
          <p>
           5
          </p>
         </td>
         <td align="left">
          <p>
           40
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Venlafaxine
          </p>
         </td>
         <td align="left">
          <p>
           17
          </p>
         </td>
         <td align="left">
          <p>
           150.0
          </p>
         </td>
         <td align="left">
          <p>
           79.5
          </p>
         </td>
         <td align="left">
          <p>
           37.5
          </p>
         </td>
         <td align="left">
          <p>
           225
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Fluvoxamine
          </p>
         </td>
         <td align="left">
          <p>
           15
          </p>
         </td>
         <td align="left">
          <p>
           114.2
          </p>
         </td>
         <td align="left">
          <p>
           66.0
          </p>
         </td>
         <td align="left">
          <p>
           50
          </p>
         </td>
         <td align="left">
          <p>
           300
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Escitalopram
          </p>
         </td>
         <td align="left">
          <p>
           10
          </p>
         </td>
         <td align="left">
          <p>
           13.0
          </p>
         </td>
         <td align="left">
          <p>
           6.7
          </p>
         </td>
         <td align="left">
          <p>
           5
          </p>
         </td>
         <td align="left">
          <p>
           20
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Fluoxetine
          </p>
         </td>
         <td align="left">
          <p>
           2
          </p>
         </td>
         <td align="left">
          <p>
           17.5
          </p>
         </td>
         <td align="left">
          <p>
           3.5
          </p>
         </td>
         <td align="left">
          <p>
           15
          </p>
         </td>
         <td align="left">
          <p>
           20
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Sertraline
          </p>
         </td>
         <td align="left">
          <p>
           4
          </p>
         </td>
         <td align="left">
          <p>
           62.5
          </p>
         </td>
         <td align="left">
          <p>
           25
          </p>
         </td>
         <td align="left">
          <p>
           50
          </p>
         </td>
         <td align="left">
          <p>
           100
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Paroxetine
          </p>
         </td>
         <td align="left">
          <p>
           1
          </p>
         </td>
         <td align="left">
          <p>
           10
          </p>
         </td>
         <td align="left">
          <p>
           0
          </p>
         </td>
         <td align="left">
          <p>
           10
          </p>
         </td>
         <td align="left">
          <p>
           10
          </p>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Mwingiliano na Dawa Nyingine
    </title>
    <p id="Par15">
     Hatukutoa dawa wenyewe lakini tulitoa ushauri, hivyo jukumu la mwisho lilibaki kwa daktari anayetoa dawa. Wagonjwa wengi walikuwa wamepewa mirtazapine, nortriptyline au quetiapine kusaidia kulala. Zote tatu huongeza—kama SSRIs—kipindi cha QTc, mbili za kwanza ambazo pia hubeba hatari ya ugonjwa wa serotonergic. Tulipendekeza kwanza kuondoa hizo tatu. SSRI mara nyingi husaidia watu kulala vizuri zaidi. Ikiwa sivyo, tunapendekeza syrup ya promethazine (phenothiazine ya kizazi cha kwanza), mpinzani wa sedative Histamine1 (H1) badala yake. Ili kuepuka kuboresha kidogo kwa athari ya SSRI, tulihifadhi dozi kuwa chini iwezekanavyo (5 mg hadi 15 mg usiku). Watu wengi walitumia desloratadine (mpinzani wa H1) kwa sababu ya mzio na kinadharia hiyo inaweza pia kuboresha athari ya SSRI. Omeprazole (kizuizi cha CYP2C19) huongeza kiwango cha serotonini. Lakini tuliacha kuongeza SSRI ikiwa kulikuwa na athari nyingi za pembeni na kurudi nyuma ikiwa ni lazima. Watu waliotumia omeprazole (n = 5), walipokea: venlafaxine 37.5 mg; paroxetine 10 mg; citalopram 2 × 20 mg; escitalopram 5 mg. Aspirin na diclofenac (kuongeza hatari ya kutokwa na damu) pia zilishauriwa kupunguzwa sana au kuondolewa. Matumizi ya solifenacin na salmeterol (fluticasone) (zote mbili huongeza kipindi cha QTc) haziwezi kupunguzwa na zilichanganywa na fluvoxamine 100 mg na 75 mg, mtawalia
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Ujumuishaji na Uondoaji
    </title>
    <p id="Par16">
     Kuanzia Novemba 1, 2022, wagonjwa wa PCS waliowasiliana nasi, au waliowasiliana nasi hapo awali na kuanza SSRI mapema, waliombwa kurudisha dodoso lililokamilishwa na idhini ya taarifa kwa usindikaji wa data zote kwa njia ya majina bandia. Pia walitoa ruhusa ya kuwasiliana tena na maswali ya ziada kwa madhumuni ya utafiti. Ili kufikia kiasi cha kutosha, tulilenga kupokea dodoso 100. Baada ya kupokea dodoso 101 mnamo Machi 4, 2023, tulifunga awamu ya uwanja wa utafiti huu. Tulianza na dodoso 101 za awali, bila uteuzi wowote, bila kujali sifa za idadi ya watu, uzito wa ugonjwa wao au matokeo ya matibabu. Tulijumuisha tu wagonjwa wenye maambukizi ya muda mfupi ya Covid-19, yaliyothibitishwa na PCR au kipimo cha antijeni, ikifuatiwa na dalili za PCS, ambao walitibiwa na SSRI. Wagonjwa watatu walikuwa wameendeleza PCS baada ya chanjo ya Covid-19. Wote watatu walikuwa na maambukizi ya Covid-19 kabla tu. Utambuzi wa PCS kufuatia maambukizi ya Covid-19 ulifanywa na GP na/au mtaalamu wa matibabu kulingana na muundo wa kliniki wa dalili. Tazama Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     <sup/>
     .
     <fig id="Fig1" position="float">
      <label>
       Figure 1
      </label>
      <caption xml:lang="en">
       <p>
        Chati ya mtiririko wa ujumuishaji na uondoaji.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig1_HTML.png" id="MO1" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par17">
     Vigezo vya kutengwa kwa ushiriki vilikuwa: matumizi ya muda mrefu ya SSRI kwa ugonjwa wa huzuni/wasiwasi (2x), ushiriki wa wakati mmoja katika utafiti mwingine wa dawa (1x), na kusitisha ndani ya wiki 4-6 baada ya kuanza SSRI kutokana na madhara (3x). Hii iliacha idadi ya wagonjwa 95, wote wakiwa raia wa Uholanzi. Wagonjwa ambao walikuwa wamesitisha SSRI baada ya zaidi ya wiki 4 kwa sababu ya madhara, au ambao hawakuwa wameongeza dozi kwa sababu ya madhara, walijumuishwa.
    </p>
   </sec>
   <sec id="Sec7">
    <title>
     Dodoso
    </title>
    <p id="Par18">
     Dodoso zote zilizopokelewa zilishughulikiwa kwa njia ya majina bandia. Dodoso ziliwekwa kwa namba na data iliingizwa kwenye faili za Excel. Ufunguo wenye majina na namba ulisimamiwa kwa uangalifu na ulitumiwa tu kupata taarifa zaidi ikiwa ni lazima kwa madhumuni ya utafiti.
    </p>
    <p id="Par19">
     Dodoso lilikuwa na sehemu mbili. Sehemu A iliripoti hali kabla, na Sehemu B iliripoti hali baada ya matibabu na SSRI.
    </p>
    <p id="Par20">
     Sehemu A ilijumuisha maswali ya wazi na yaliyofungwa kuhusu demografia, dalili za PCS, historia ya matibabu, hali ya vitamini D na B
     <sub>
      12
     </sub>
     , matumizi ya dawa, virutubisho vya lishe, matibabu mengine ya awali na matokeo yake. Ikiwa hali ya vitamini D na B
     <sub>
      12
     </sub>
     haikujulikana, tuliwaomba wapime na daktari wao na kuongeza ikiwa ni lazima kabla ya kuanza SSRI. Vitamini D inaweza kudhibiti mfumo wa kinga na viwango vya chini vya vitamini D vinahusishwa na PCS
     <sup>
      <xref ref-type="bibr" rid="CR41">
       41
      </xref>
      ,
      <xref ref-type="bibr" rid="CR42">
       42
      </xref>
     </sup>
     . Vitamini B
     <sub>
      12
     </sub>
     inaweza kusaidia kusawazisha majibu ya kinga ili kupambana vyema na maambukizi ya virusi
     <sup>
      <xref ref-type="bibr" rid="CR43">
       43
      </xref>
     </sup>
     . Pia tuliuliza kuhusu muda kati ya Covid-19 na PCS. Dodoso pia lilikuwa na alama kwa ukali wa malalamiko 8 ya kawaida ya PCS katika sehemu A na sehemu B (angalia hapa chini). Washiriki waliombwa kukamilisha sehemu A mara baada ya kupokea. Swali la wazi kuhusu malalamiko ya PCS liliwapa wagonjwa fursa ya kuripoti dalili za PCS ambazo hazijawahi kuelezwa. Dodoso zilizopo kama vile Chalder Fatigue Scale au Canadian Consensus Criteria, zote zilizotengenezwa kwa ME/CFS, zilionekana kuwa hazifai kwa madhumuni haya
     <sup>
      <xref ref-type="bibr" rid="CR44">
       44
      </xref>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
     </sup>
     .
    </p>
    <p id="Par21">
     Sehemu B ilikamilishwa angalau wiki 4 hadi 6 baada ya kuanza na SSRI. Katika Sehemu B, washiriki waliulizwa ni SSRI gani iliyotumika, kwa dozi gani walianza, titration na dozi ya mwisho na kuhusu mwanzo wa majibu yoyote na madhara. Katika swali la wazi kuhusu matokeo, tuliuliza kuhusu kupungua kwa dalili yoyote. Orodha ya Upimaji kwa ukali wa malalamiko 8 ilirudiwa katika sehemu B.
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Udhibiti wa Kuripoti Nyuma
    </title>
    <p id="Par22">
     Wagonjwa 61—ambao chini ya mwongozo wetu—walikuwa tayari wameanza kutumia SSRI kabla ya Novemba 1, 2022, waliombwa kukamilisha sehemu A ya dodoso kwa njia ya nyuma. Kwa kundi hili, uchambuzi ulitumia barua pepe ya kwanza kwetu yenye maelezo ya malalamiko ya awali ili kutambua kipimo cha msingi. Katika visa vyote, malalamiko ya PCS kama ilivyoelezwa katika dodoso yalilingana na muhtasari wa malalamiko katika barua pepe ya usajili. Kwa hivyo, kwa kundi hili pia tuliweza kutegemea malalamiko kama ilivyoelezwa katika dodoso.
    </p>
   </sec>
   <sec id="Sec9">
    <title>
     Hatua Tatu za Kutathmini Matokeo ya Matibabu
    </title>
    <p id="Par23">
     Tulitumia vipimo vitatu kutathmini matokeo ya matibabu: 'matokeo ya swali wazi', 'orodha ya alama' na 'alama ya kengele'.
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Swali Wazi Kuhusu Matokeo katika Sehemu B ya Dodoso
    </title>
    <p id="Par24">
     Kama jibu kwa swali wazi kuhusu matokeo, wagonjwa 93 kati ya 95 walielezea matokeo ya matibabu ya SSRI kwa maneno yao wenyewe. Tuliunda mwongozo wa kupima majibu ya Matokeo ya Swali Wazi. Majibu yalipimwa katika makundi 5: kuboreshwa kwa nguvu (4), kuboreshwa vizuri (3), kuboreshwa kwa kiasi (2), kuboreshwa kwa wastani (1) na kutokuboreka (0). Watafiti wawili huru ambao hawakuhusika katika utafiti walitumia mwongozo huu kwa swali la wazi, pamoja na mmoja wa waandishi. Kulingana na matumizi haya 3, uaminifu kati ya wapimaji wa mwongozo ulionyesha "uaminifu mzuri" (ICC = 0.74; Cronbach’s alpha = 0.89). Tunarejelea kipimo hiki cha kwanza cha athari kama 'Matokeo ya Swali Wazi'.
    </p>
   </sec>
   <sec id="Sec11">
    <title>
     Orodha ya Alama
    </title>
    <p id="Par25">
     Kama kipimo cha pili cha athari wagonjwa waliulizwa katika Sehemu A ya
     <italic>
      dodoso
     </italic>
     kuonyesha ukali wa dalili 8 za kawaida za PCS (ukungu wa ubongo, uchovu sugu, mzigo wa hisia, maumivu ya kichwa, mapigo ya moyo, upungufu wa pumzi, udhaifu wa misuli na maumivu ya misuli), pamoja na "dalili nyingine yoyote," kwenye kipimo kutoka 0 (sio shida) hadi 10 (shida sana). Alama hii ya ukali ilipaswa kukamilishwa kabla ya kuanza SSRI. Katika Sehemu B ya dodoso, iliyokamilishwa angalau wiki 4 hadi 6 baada ya kuanza matibabu, ukali wa malalamiko haya ulipimwa tena. Tofauti kati ya alama 8 kabla na alama wiki 4 hadi 6 baada ya kuanza matibabu, inatumika kama kipimo cha pili cha matokeo.
    </p>
    <p id="Par26">
     Kati ya wagonjwa 95, 77 walikamilisha Orodha ya Alama. Ikiwa mgonjwa hakuwa na malalamiko, hakuipima. Wagonjwa kumi na wanane walionyesha ugumu katika kupima orodha, kwa sehemu kwa sababu ya utofauti mkubwa katika ukali wa malalamiko. Wagonjwa 18 ambao hawakujaza Orodha ya Alama hawakutofautiana na wagonjwa 77 ambao walijaza Orodha ya Alama kwa mujibu wa Swali Wazi la Matokeo, kama ilivyopimwa na Mtihani wa Bayesian Mann–Whitney U (angalia "
     <xref ref-type="sec" rid="Sec13">
      Uchambuzi wa Takwimu
     </xref>
     ") kwa kulinganisha makundi (BF = 0.63). Tunarejelea kipimo hiki cha pili cha athari kama "Orodha ya Alama".
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     Alama ya Bell
    </title>
    <p id="Par27">
     Kama kipimo cha tatu cha athari, alama ya Utendaji ya Bell ilitumika
     <sup>
      <xref ref-type="bibr" rid="CR45">
       45
      </xref>
     </sup>
     . Kipimo hiki kimeundwa kutathmini uwezo wa utendaji kwa wagonjwa wazima wa ME/CFS. Kauli kumi na moja zinaelezea hali ya mgonjwa kama vile kiwango cha dalili wakati wa kupumzika na wakati wa mazoezi, kiwango cha shughuli, na uwezo wa kufanya kazi, kusafiri na kujitunza. Kipimo hiki kinapimwa kwa vitengo vya 10 kutoka 0 hadi 100. Mfano wa kauli, alama 20:
     <italic>
      ‘Anaweza kutoka nje mara moja au mbili kwa wiki. Dalili za wastani hadi kali. Anaweza kuzingatia kwa saa moja au chini kwa siku’.
     </italic>
     Na alama 50:
     <italic>
      ‘Anaweza kufanya kazi au shughuli sawa nyumbani kwa takriban saa 4-5. Dalili nyingi ni za wastani. Mapumziko ya kila siku yanahitajika’.
     </italic>
     Tuliwasilisha kwa wagonjwa mnamo Februari 2023, kwa hivyo ilikamilishwa kwa sehemu kwa kurudi nyuma. Wagonjwa themanini walijibu. Alama ya Bell ilikamilishwa mara tatu: kupima hali yao kwa kurudi nyuma kabla ya maambukizi ya Covid-19, kabla tu ya matibabu na SSRI wakati wa PCS, na wiki 4 hadi 6 baada ya matibabu na SSRI. Kukamilisha hakukuwa rahisi kwa wagonjwa 15 kwa sababu ya tofauti kubwa katika ukali wa dalili. Wagonjwa 15 ambao hawakukamilisha alama ya Bell hawakutofautiana na wagonjwa 80 ambao walikamilisha alama ya Bell katika matokeo ya "Matokeo ya swali wazi" (BF = 0.27).
    </p>
    <p id="Par28">
     Kwa wagonjwa 14 wenye ugonjwa wa kingamwili, ME/CFS iliyokuwepo awali au virusi vya Dengue katika historia ya zamani, ukali wa uchovu kabla ya kuanza kwa maambukizi ya Covid-19/PCS pia ulikaguliwa. Hii ilionyeshwa katika alama yao ya awali ya Bell, ambayo walipata alama ya chini sana kuliko wengine (kwa wastani 83.5 dhidi ya 96.3, mtawalia; BF = 87.5).
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Uchambuzi wa Takwimu
    </title>
    <p id="Par29">
     Takwimu kutoka kwa dodoso, orodha za alama, na alama za Bell katika Excel zilipakiwa kwenye MATLAB R2022b kwa uchambuzi zaidi na kwa kuunda jedwali na takwimu za matokeo. Kwa uchambuzi wa takwimu tulitumia JASP (toleo la 0.17.1), kifurushi cha programu kwa takwimu za Bayesian
     <sup>
      <xref ref-type="bibr" rid="CR46">
       46
      </xref>
     </sup>
     . Upimaji wa nadharia ya Bayesian unakadiria moja kwa moja nguvu ya ushahidi kwa nadharia moja (H1) juu ya nadharia mbadala (null) (H0), na ushahidi huu unakokotolewa na Bayes Factor (BF)
     <sup>
      <xref ref-type="bibr" rid="CR47">
       47
      </xref>
     </sup>
     . BF ya 10 kwa mfano, inaonyesha kwamba H1 ina uwezekano mara 10 zaidi kuliko H0, kutokana na data iliyotazamwa. Kinyume chake, BF ya 0.1 inaonyesha kwamba H0 ina uwezekano mara 10 zaidi kuliko H1. Hivyo, tofauti na takwimu za jadi, njia hii inaruhusu kukadiria moja kwa moja ushahidi kwa niaba ya nadharia mbadala, kwa mfano, ya kutokuwepo tofauti ya kikundi. BF ya 1 hadi 3 inaonyesha ushahidi wa anekdoti, 3 hadi 10 ushahidi wa wastani, 10 hadi 30 ushahidi thabiti, 30 hadi 100 ushahidi thabiti sana, na 100 au zaidi ushahidi thabiti sana kwa niaba ya H1
     <sup>
      <xref ref-type="bibr" rid="CR48">
       48
      </xref>
      <xref ref-type="bibr" rid="CR47">
       47
      </xref>
     </sup>
     . Katika uchambuzi wetu wote wa Bayesian tulitumia vigezo vya mfano vya chaguo-msingi na usambazaji wa awali kama ilivyowekwa na JASP.
    </p>
    <p id="Par30">
     Tulichambua matokeo kwa dalili kwa kutumia ANOVA ya Bayesian ya vipimo vilivyorudiwa, na vipengele viwili vya matibabu ya SSRI (kabla dhidi ya baada) na dalili (8). Kwa matokeo kama yalivyokamatwa na alama za Bell, tulitumia mtihani wa t wa sampuli tegemezi ya Bayesian kupima tofauti katika alama ya Bell kati ya 'wakati wa PCS' na 'baada ya matibabu ya SSRI'.
    </p>
    <p id="Par31">
     Uhusiano kati ya vipimo 10 vya matokeo (yaani, matokeo ya swali wazi, alama 8 za dalili, na alama ya Bell) ulichambuliwa kwa kutumia uhusiano wa kiwango cha Spearman kati ya wagonjwa. Zaidi ya hayo, tulihesabu alama za dalili zilizojumuishwa (kwa kujumlisha alama 8 za dalili za kibinafsi) na tukahusisha kipimo hiki kilichojumuishwa na matokeo kwenye Matokeo ya swali wazi na alama ya Bell.
    </p>
   </sec>
  </sec>
  <sec id="Sec14" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec15">
    <title>
     Sifa za Kidemografia na Kliniki
    </title>
    <p id="Par32">
     Umri wa wastani ulikuwa miaka 43 ± 11.5 (SD; min–max: 21–72) na wanawake walikuwa wengi zaidi (uwiano wa wanaume kwa wanawake 1:5.8). 76% walikuwa wakiishi na mwenza na 62% walikuwa na mtoto mmoja au zaidi. Zaidi ya robo tatu walikuwa na elimu ya juu (idadi ya watu wa NL: zaidi ya theluthi moja). Asilimia ya wagonjwa wanaofanya kazi katika sekta ya afya (31%) au elimu (18%) ilikuwa juu zaidi (BF = 591 na BF = 558, mtawalia) kuliko katika idadi ya watu wa Uholanzi kwa ujumla: kati ya milioni 10.0 walioajiriwa, milioni 1.4 (14%) wanafanya kazi katika sekta ya afya, na 577,000 (5.7%) katika elimu. Maambukizi ya Covid-19, isipokuwa kwa wagonjwa watatu, hayakuhitaji kulazwa hospitalini. Kabla ya kuanza kwa SSRI, wagonjwa walikuwa na PCS kwa wastani wa miezi 15 ± 8.1 (min–max: 3–36), na mara nyingi walikuwa na ulemavu mkubwa. 30–40% walihisi ganzi (dalili ya kutengana) au huzuni kwa sababu ya PCS yao lakini hawakuwa na unyogovu (DSM-5). Wagonjwa wawili walipata unyogovu wa kliniki (kipindi cha kwanza) na wawili walipata shida ya wasiwasi (vigezo vya DSM-5).
    </p>
    <p id="Par33">
     Wagonjwa 76 (80%, n = 93) walikuwa na magonjwa mengine ambayo ni hatari kwa PCS
     <sup>
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
     </sup>
     . Tazama Jedwali
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     <sup/>
     . Wagonjwa 46 (49.5%) walikuwa na pumu au mzio: homa ya nyasi, mug wort (aina ya homa ya nyasi), vumbi la nyumba, nikeli, paka, wanyama wengine wa kipenzi, zabibu, samakigamba, ndege, kuumwa na wadudu, amoxicillin, clamoxyl, vibramycin, ukungu, mpira, manukato, vipodozi, gluten, jua, kiwi, plasta, karanga, njugu, na wakati mwingine mzio mwingi kwa wakati mmoja. Wagonjwa tisa walikuwa na ugonjwa wa kinga mwili: Sjogren’s, arthritis ya baridi yabisi, Cushing’s, hypothyroidism, lichen planus, ugonjwa wa celiac, na viwango vya juu vya kingamwili za anti-nuclear (ANA); watatu walikuwa na ME/CFS; wagonjwa wawili walikuwa wamepata virusi vya Epstein-Barr na mmoja virusi vya Dengue; kumi walikuwa na ugonjwa wa tishu unganishi: fibromyalgia, CRPS I, hemihypertrophy, na osteoarthritis. Saba walikuwa na ugonjwa wa akili, ikiwa ni pamoja na watatu wenye AD(H)D, wawili wenye unyogovu, na wawili wenye wasiwasi au shida ya hofu. Wagonjwa wawili walikuwa na thrombophilia ya factor V Leiden.
     <table-wrap id="Tab2">
      <label>
       Jedwali 2
      </label>
      <caption xml:lang="en">
       <p>
        Sifa za kidemografia na kimatibabu na majibu kwa SSRI.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" rowspan="2"/>
         <th align="left" rowspan="2">
          <p>
           Jumla (n = 95)
          </p>
         </th>
         <th align="left" colspan="5">
          <p>
           Matokeo ya swali wazi (n = 93)
          </p>
         </th>
         <th align="left" rowspan="2">
          <p>
           Tofauti za kikundi
          </p>
         </th>
        </tr>
        <tr>
         <th align="left">
          <p>
           0 (n = 9)
          </p>
         </th>
         <th align="left">
          <p>
           1 (n = 25)
          </p>
         </th>
         <th align="left">
          <p>
           2 (n = 25)
          </p>
         </th>
         <th align="left">
          <p>
           3 (n = 27)
          </p>
         </th>
         <th align="left">
          <p>
           4 (n = 7)
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           Umri (min–max)
          </p>
         </td>
         <td align="left">
          <p>
           43.5 (21–72)
          </p>
         </td>
         <td align="left">
          <p>
           47.7 (25–72)
          </p>
         </td>
         <td align="left">
          <p>
           44.3 (21–68)
          </p>
         </td>
         <td align="left">
          <p>
           43.1 (22–62)
          </p>
         </td>
         <td align="left">
          <p>
           40.7 (25–58)
          </p>
         </td>
         <td align="left">
          <p>
           46.3 (30–57)
          </p>
         </td>
         <td align="left">
          <p>
           Hapana (BF = 0.13)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Jinsia (f/m)
          </p>
         </td>
         <td align="left">
          <p>
           80/15
          </p>
         </td>
         <td align="left">
          <p>
           8/1
          </p>
         </td>
         <td align="left">
          <p>
           19/6
          </p>
         </td>
         <td align="left">
          <p>
           21/4
          </p>
         </td>
         <td align="left">
          <p>
           24/3
          </p>
         </td>
         <td align="left">
          <p>
           6/1
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 0.34)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kulazwa wakati wa COVID
          </p>
         </td>
         <td align="left">
          <p>
           3 (3.2%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (33.3%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0%)
          </p>
         </td>
         <td align="left">
          <p>
           Ndio (BF = 16.4)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="8">
          <p>
           Historia ya matibabu
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Magonjwa ya kinga mwili
          </p>
         </td>
         <td align="left">
          <p>
           9 (9.5%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (11.1%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (8.0%)
          </p>
         </td>
         <td align="left">
          <p>
           4 (16.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (3.7%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 0.48)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Pumu/aleji
          </p>
         </td>
         <td align="left">
          <p>
           46 (48.4%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (22.2%)
          </p>
         </td>
         <td align="left">
          <p>
           14 (56.0%)
          </p>
         </td>
         <td align="left">
          <p>
           15 (60.0%)
          </p>
         </td>
         <td align="left">
          <p>
           12 (44.4%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (42.9%)
          </p>
         </td>
         <td align="left">
          <p>
           Hapana (BF = 0.22)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Pfeiffer/Dengue
          </p>
         </td>
         <td align="left">
          <p>
           3 (3.2%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (11.1%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 1.05)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Magonjwa ya tishu unganishi
          </p>
         </td>
         <td align="left">
          <p>
           10 (10.5%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (11.1%)
          </p>
         </td>
         <td align="left">
          <p>
           5 (20.0%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (12.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (3.7%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 1.05)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           ME/CVS
          </p>
         </td>
         <td align="left">
          <p>
           3 (3.2%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (3.7%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 0.47)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Thrombophilia ya Factor V Leiden
          </p>
         </td>
         <td align="left">
          <p>
           2 (2.1%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 0.58)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Magonjwa ya akili: wasiwasi, hofu, unyogovu, au AD(H)D
          </p>
         </td>
         <td align="left">
          <p>
           7 (7.4%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (11.1%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (12.0%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (7.4%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           ~ (BF = 0.38)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Pengo la muda kwa miezi kati ya kuanza PCS na SSRI (min–max)
          </p>
         </td>
         <td align="left">
          <p>
           15 (3–36)
          </p>
         </td>
         <td align="left">
          <p>
           20 (9–34)
          </p>
         </td>
         <td align="left">
          <p>
           16 (3–31)
          </p>
         </td>
         <td align="left">
          <p>
           14 (3–36)
          </p>
         </td>
         <td align="left">
          <p>
           14 (6–33)
          </p>
         </td>
         <td align="left">
          <p>
           15 (3–26)
          </p>
         </td>
         <td align="left">
          <p>
           Hapana (BF = 0.18)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="8">
          <p>
           Aina ya SSRI: agonists za sigma1
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Citalopram
          </p>
         </td>
         <td align="left">
          <p>
           46 (48.4%)
          </p>
         </td>
         <td align="left">
          <p>
           4 (44.4%)
          </p>
         </td>
         <td align="left">
          <p>
           10 (40.0%)
          </p>
         </td>
         <td align="left">
          <p>
           17 (68.0%)
          </p>
         </td>
         <td align="left">
          <p>
           13 (48.1%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (28.6%)
          </p>
         </td>
         <td align="left" rowspan="7">
          <p>
           Hapana (BF = 0.096)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Fluvoxamine
          </p>
         </td>
         <td align="left">
          <p>
           15 (15.8%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (22.2%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (8.0%)
          </p>
         </td>
         <td align="left">
          <p>
           3 (12.0%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (7.4%)
          </p>
         </td>
         <td align="left">
          <p>
           4 (57.1%)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Venlafaxine
          </p>
         </td>
         <td align="left">
          <p>
           17 (17.9%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (22.2%)
          </p>
         </td>
         <td align="left">
          <p>
           7 (28.0%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (8.0%)
          </p>
         </td>
         <td align="left">
          <p>
           5 (18.5%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (14.3%)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Escitalopram
          </p>
         </td>
         <td align="left">
          <p>
           10 (10.5%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (11.1%)
          </p>
         </td>
         <td align="left">
          <p>
           4 (16.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           4 (14.8%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Fluoxetine
          </p>
         </td>
         <td align="left">
          <p>
           2 (2.1%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (3.7%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           Aina ya SSRI: Antagonists za Sigma 1
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Sertraline/Paroxetine
          </p>
         </td>
         <td align="left">
          <p>
           5 (5.4%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
         <td align="left">
          <p>
           1 (4.0%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (8.0%)
          </p>
         </td>
         <td align="left">
          <p>
           2 (7.4%)
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0%)
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        Safu ya 'Tofauti za kikundi' inaonyesha kiwango cha ushahidi wa tofauti ya kikundi (BF &gt; 1) au hakuna tofauti ya kikundi (BF &lt; 1) kati ya vikundi 5 kwenye sifa husika. ~ inaonyesha hakuna ushahidi wenye nguvu katika mwelekeo wowote (yaani, BF kati ya 1/3 na 3). Athari ya aina ya SSRI kwenye matokeo ya swali wazi inajaribiwa katika ANOVA moja ya Bayesian. Kumbuka kwamba mgonjwa mmoja alitumia sertraline mwanzoni (matokeo 0) lakini alibadilisha hadi citalopram (matokeo 2).
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
    <p id="Par34">
     Katika Orodha ya Alama (n = 77), 100% ya wagonjwa waliripoti brainfog na uchovu na 98.7% waliripoti mzigo wa hisia. Maumivu ya kichwa na mapigo ya moyo yaliripotiwa kwa 90.9 na 88.3%, mtawalia. Udhaifu wa misuli ulitokea kwa 85.7%, maumivu ya misuli na mshtuko kwa 80.5%. Katika swali la wazi kuhusu dalili za PCS, 100% waliripoti PEM (n = 95). Wagonjwa kumi na nne waliripoti dalili kali za kutengana kama vile derealization au depersonalization. Mgonjwa mmoja alieleza hivi: “Ninaamka kila asubuhi bila kumbukumbu”.
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Matokeo Yaliyotolewa
    </title>
    <sec id="Sec17">
     <title>
      Swali Wazi Kuhusu Matokeo
     </title>
     <p id="Par35">
      63.4% ya wagonjwa (n = 93) waliripoti kupungua kwa dalili baada ya matibabu na SSRI na kuboreshwa kwa kiwango cha wastani mzuri (26.9%), mzuri (29%), na nguvu (7.5%) (tazama Fig.
      <xref ref-type="fig" rid="Fig2">
       2
      </xref>
      ). Wagonjwa 29 (31.1%) waliripoti kuboreshwa kwa usingizi. Wagonjwa 67 (72.0%) walielezea kupungua kwa PEM. Wagonjwa wanne waliripoti kupungua kwa dalili za njia ya utumbo. Kwa mgonjwa mmoja, homa ilikuwa imetoweka, na mgonjwa mmoja aliweza kutafuna vizuri tena. Kwa mgonjwa mmoja, PCS ilisababisha tezi yake ya adrenal pekee inayofanya kazi kushindwa, ambayo alitibiwa na hydrocortisone. Baada ya SSRI, tezi yake ya adrenal ilipona na aliweza kupunguza dozi ya hydrocortisone. Zaidi ya hayo, kwa mgonjwa huyu, PCS iliongeza TSH yake kutoka 2.5 mlU/l hadi 5.5 mlU/l (N 0.3–4.2 mlU/l). Matokeo yake, T4 yake huru iliongezeka kutoka 14 pmol/l hadi 19 pmol/l (juu ya kawaida). Baada ya matibabu na SSRI, TSH yake na T4 huru zilirudi kuwa za kawaida. Wagonjwa kumi na nne wenye dalili za kutengana waliripoti kuwa hizi zilikuwa zimetoweka. Hatimaye, inashangaza kwamba wagonjwa mara nyingi huripoti kuwa SSRI inazalisha ongezeko la mwitikio katika miezi baada ya kuanza. Wagonjwa 24 ambao walichukua SSRI kwa zaidi ya miezi sita waliripoti kuwa matokeo yalidumishwa.
      <fig id="Fig2" position="float">
       <label>
        Figure 2
       </label>
       <caption xml:lang="en">
        <p>
         Matokeo ya swali wazi: uboreshaji kama ulivyokamatwa na swali wazi (n = 93).
        </p>
       </caption>
       <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig2_HTML.png" id="MO2" mime-subtype="PNG" specific-use="web"/>
      </fig>
     </p>
     <p id="Par36">
      Hakukuwa na ushahidi wa kuunga mkono au kupinga tofauti katika matokeo yaliyopimwa na swali la wazi kulingana na kama wagonjwa walipokea sigma1 agonists au antagonists (BF = 0.43). Ikiwa tutajumuisha mgonjwa ambaye alibadilisha kutoka sertraline (hakuna kuboreshwa) hadi citalopram (na kuboreshwa kwa wastani mzuri), hakuna tofauti kubwa inayobaki (BF 0.39).
     </p>
    </sec>
    <sec id="Sec18">
     <title>
      Orodha ya Alama: Uboreshaji kwa Kila Malalamiko
     </title>
     <p id="Par37">
      Matokeo makuu ni kwamba kuna ushahidi wa takwimu wenye nguvu kwa athari chanya kwenye PCS wakati inatibiwa na SSRI (Fig.
      <xref ref-type="fig" rid="Fig3">
       3
      </xref>
      ). Matokeo haya yanaungwa mkono na tofauti ya Bayesian ya ANOVA na mambo mawili ya matibabu ya SSRI (kabla/baada) na malalamiko (8), ambayo inaonyesha kuwa kuna ushahidi wenye nguvu wa athari muhimu ya matibabu ya SSRI (BF = 5.0 × 1010 mara kubwa zaidi kwa mfano na matibabu ya SSRI kuliko mfano bila). Zaidi ya hayo, kuna ushahidi wenye nguvu wa athari ya mwingiliano (BF = 64.6 mara kubwa zaidi kwa mfano na mwingiliano), ikimaanisha kuwa athari ya matibabu ya SSRI inatofautiana na malalamiko. Brainfog na mzigo wa hisia ulipungua zaidi (3.8 na 3.6 pts, mtawalia), maumivu ya misuli na udhaifu ulijibu kidogo (2.1 na 1.9 pts, mtawalia).
      <fig id="Fig3" position="float">
       <label>
        Figure 3
       </label>
       <caption xml:lang="en">
        <p>
         Uboreshaji kwa kila malalamiko. Kabla (rangi ya chungwa) na baada (kijani) ya kuanza SSRI katika michoro ya violin kwa kila malalamiko. Sehemu za giza zinaonyesha 50% ya wagonjwa, wakati sehemu za juu na za chini za mwanga zinaonyesha 25% ya juu na ya chini, mtawalia. Tazama lebo ya mhimili wa x kwa dalili na idadi ya wagonjwa (n = x) ambao walipata malalamiko hayo.
        </p>
       </caption>
       <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig3_HTML.png" id="MO3" mime-subtype="PNG" specific-use="web"/>
      </fig>
     </p>
     <p id="Par38">
      Wagonjwa wenye fibromyalgia (n = 5), ambapo maumivu ya misuli ni dalili kuu, waliripoti kuboreshwa kidogo au hakuna baada ya kutumia SSRI. Miongoni mwa malalamiko mengine, wagonjwa wanane (10.4%, n = 77) waliripoti kupungua kwa kiasi kikubwa kwa PEM kwa wastani wa zaidi ya pointi 5.1. Kwa wagonjwa 59 (76.6%), athari hii ilionekana kwa njia isiyo ya moja kwa moja katika kupungua kwa mapigo ya moyo, uchovu na upungufu wa pumzi. Wagonjwa wanane kati ya 14 wenye tinnitus waliripoti kwamba malalamiko haya yalipungua, kwa wanne haikutokea na kwa mmoja malalamiko yalizidi kuwa mabaya.
     </p>
    </sec>
    <sec id="Sec19">
     <title>
      Alama ya Bell: Uboreshaji wa Utendaji
     </title>
     <p id="Par39">
      Kama ilivyo kwa tofauti za alama kwenye malalamiko 8, pia tunapata ushahidi wa takwimu wenye nguvu kwa athari chanya ya SSRI kwenye alama za Bell (BF = 9.6 × 1017). Kuna kupungua kwa nguvu katika utendaji baada ya maambukizi ya Covid-19 na PCS, kutoka wastani wa 94.2 hadi 23.5 kwenye Alama ya Utendaji ya Bell: kutoka maisha yenye afya na uwezo wa kufanya kazi hadi ulemavu mkubwa, ambapo alama ya Bell ya 10 au chini ina maana ya kulazwa kitandani (angalia Fig.
      <xref ref-type="fig" rid="Fig4">
       4
      </xref>
      ). Tofauti hii inaungwa mkono na tofauti ya Bayesian ya t-test (BF = 9.1 × 1052). Matibabu na SSRI hutoa ongezeko la wastani hadi 47.2: kwa kujitunza kikamilifu, ununuzi, kutembea, na (kurudi kwa sehemu) kazini. Ingawa hii inaweza kuonekana kama maendeleo madogo kwenye kiwango kamili, ni muhimu kutambua kwamba alama ya Bell si ya mstari: maboresho makubwa ya kibinafsi hutokea hadi alama 50.
      <fig id="Fig4" position="float">
       <label>
        Figure 4
       </label>
       <caption xml:lang="en">
        <p>
         Alama za Bell. Alama za Bell kabla ya maambukizi ya Covid-19 na PCS, wakati wa PCS na baada ya matibabu na SSRI katika michoro tofauti ya violin (n = 80). Kipindi ambacho 50% ya wagonjwa huangukia kinaonyeshwa na maeneo ya giza, ilhali kipindi ambacho 25% ya juu na ya chini ya wagonjwa huangukia kinaonyeshwa na maeneo ya mwanga.
        </p>
       </caption>
       <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig4_HTML.png" id="MO4" mime-subtype="PNG" specific-use="web"/>
      </fig>
     </p>
     <p id="Par40">
      Kati ya wagonjwa 36 ambao walitumia SSRI kwa miezi 2 au chini, 17 (47.2%) waliripoti kwamba bado waliona kupungua kwa dalili baada ya kipimo. Kwa mgonjwa mmoja hii ilikuwa kweli baada ya miezi 4, kwa mgonjwa mmoja baada ya miezi 6 na kwa mgonjwa mmoja baada ya miezi 7.
     </p>
    </sec>
   </sec>
   <sec id="Sec20">
    <title>
     Uhusiano Kati ya Hatua Tatu za Athari
    </title>
    <p id="Par41">
     Vipimo vitatu tofauti vya athari vinaonyesha uhusiano mkubwa wa maana kati yao (angalia Jedwali
     <xref ref-type="table" rid="Tab3">
      3
     </xref>
     na Fig.
     <xref ref-type="fig" rid="Fig5">
      5
     </xref>
     kwa Rho na
     <italic>
      p
     </italic>
     thamani za jozi). Hii ni, wagonjwa ambao wanaboresha sana kwenye kipimo kimoja cha athari (mfano brainfog) pia wanaboresha sana kwenye vipimo vingine vya athari (mfano mzigo wa hisia), na kinyume chake. Inavutia kutambua kwamba alama za Bell na matokeo ya Maswali ya Wazi yanahusiana sana na maboresho maalum ya malalamiko (isipokuwa maumivu ya kichwa na matokeo ya Maswali ya Wazi). Hii inaungwa mkono zaidi na uhusiano mkubwa wa maana kati ya maboresho ya pamoja kwenye malalamiko yote manane na alama za Bell (Rho = 0.63,
     <italic>
      p
     </italic>
     = 5.5 × 10; paneli ya kushoto katika Fig.
     <xref ref-type="fig" rid="Fig5">
      5
     </xref>
     a), na uhusiano mkubwa wa maana kati ya maboresho haya ya pamoja na matokeo ya Maswali ya Wazi (Rho = 0.56,
     <italic>
      p
     </italic>
     = 6.4 × 10 paneli ya kati katika Fig.
     <xref ref-type="fig" rid="Fig5">
      5
     </xref>
     a). Zaidi ya hayo, matokeo ya Maswali ya Wazi pia yalihusiana sana na alama ya Bell (Rho = 0.69,
     <italic>
      p
     </italic>
     = 1.4 × 10; paneli ya kulia katika Fig.
     <xref ref-type="fig" rid="Fig5">
      5
     </xref>
     a). Ukweli kwamba vipimo vitatu vya matokeo vilihusiana sana na kila mmoja unaunga mkono uaminifu wao wa kibinafsi.
     <fig id="Fig5" position="float">
      <label>
       Figure 5
      </label>
      <caption xml:lang="en">
       <p>
        Uhusiano wa vipimo vya athari. (
        <bold>
         a
        </bold>
        ) Uhusiano kati ya vipimo vitatu vya athari (Spearman’s Rho), ukijumuisha alama za malalamiko 8. Nukta zinawakilisha wagonjwa binafsi. (
        <bold>
         b
        </bold>
        ) Matokeo sawa ya uhusiano lakini na malalamiko 8 kando. Rangi za giza zinaonyesha uhusiano wa juu. Ni uhusiano muhimu tu unaoonyeshwa (yaani, uhusiano na thamani ya
        <italic>
         p
        </italic>
        &gt; 0.05 zimechorwa nyeupe).
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig5_HTML.png" id="MO5" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <table-wrap id="Tab3">
      <label>
       Jedwali 3
      </label>
      <caption xml:lang="en">
       <p>
        Uhusiano wa vipimo vya athari.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left"/>
         <th align="left">
          <p>
           Brainfog
          </p>
         </th>
         <th align="left">
          <p>
           Kichwa
          </p>
         </th>
         <th align="left">
          <p>
           Uchovu sugu
          </p>
         </th>
         <th align="left">
          <p>
           Kuchochewa kupita kiasi
          </p>
         </th>
         <th align="left">
          <p>
           Dyspnea
          </p>
         </th>
         <th align="left">
          <p>
           Mapigo ya moyo
          </p>
         </th>
         <th align="left">
          <p>
           Mwili maumivu
          </p>
         </th>
         <th align="left">
          <p>
           Udhaifu wa misuli
          </p>
         </th>
         <th align="left">
          <p>
           Alama ya Bell
          </p>
         </th>
         <th align="left">
          <p>
           Swali wazi
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           Brainfog
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kichwa
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.48
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Uchovu sugu
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.53
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.32
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.008**
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Kuchochewa kupita kiasi
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.70
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.39
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.67
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Dyspnoea
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.25
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.052
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.15
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.261
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.42
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.37
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Mapigo ya moyo
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.38
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.002**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.32
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.011*
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.49
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.41
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.42
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Mwili maumivu
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.29
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.023*
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.28
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.028*
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.37
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.34
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.007**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.13
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.357
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.39
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Udhaifu wa misuli
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.46
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.38
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.49
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.40
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.42
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.001**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.33
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.010**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.51
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Alama za Bell
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.60
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.42
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.72
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.68
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.40
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.47
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.39
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.003**
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.56
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
         <td align="left"/>
        </tr>
        <tr>
         <td align="left">
          <p>
           Swali wazi
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.53
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.16
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.194
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.63
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.55
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.31
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.016*
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.30
          </p>
          <p>
           <italic>
            p
           </italic>
           = 0.013*
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.43
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.49
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left">
          <p>
           Rho = 0.69
          </p>
          <p>
           <italic>
            p
           </italic>
           &lt; 0.001***
          </p>
         </td>
         <td align="left"/>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        Uhusiano kati ya vipimo vitatu vya athari (Spearman’s Rho), ambapo idadi ya nyota inaonyesha kiwango cha umuhimu: *
        <italic>
         p
        </italic>
        &lt; 0.05, **
        <italic>
         p
        </italic>
        &lt; 0.01, ***
        <italic>
         p
        </italic>
        &lt; 0.001.
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Madhara
    </title>
    <p id="Par42">
     Wakati wa kutumia SSRI kwa ajili ya unyogovu au wasiwasi, wagonjwa kwa kawaida hupata madhara kwa wiki chache za mwanzo, baada ya hapo mwitikio huanza. Wagonjwa katika utafiti huu walielimishwa kuhusu hili. Wagonjwa 30 (31.6%, n = 95) awali walipata madhara makubwa, 52 (54.7%) walipata madhara madogo, na 13 (13.7%) hawakupata madhara yoyote. Madhara kama vile hali ya kutojisikia vizuri, maumivu ya kichwa na kizunguzungu yalikuwa sawa na dalili za PCS. Wagonjwa 72 (75.7%) hawakupata athari yoyote isipokuwa madhara katika wiki za mwanzo. Kwa wagonjwa 65/82 (79.2%) walio na madhara, haya yalipungua au kutoweka ndani ya wiki chache.
    </p>
   </sec>
   <sec id="Sec22">
    <title>
     Wasiotikia
    </title>
    <p id="Par43">
     Wagonjwa 9 (9.5%, n = 95) ambao hawakuwa na mwitikio hawakuonyesha tofauti katika umri, hatari za kiafya au muundo wa dalili za PCS ikilinganishwa na makundi mengine. Kulikuwa na tofauti katika ukali wa maambukizi ya Covid-19: kundi ambalo halikuboreka na SSRI lilionekana kuwa na dalili mbaya za awali kuliko makundi mengine kulingana na swali la wazi kuhusu dalili wakati wa maambukizi ya Covid-19. Watatu kati yao walilazwa hospitalini kwa sababu ya nimonia kali, embolism ya mapafu mara mbili na thrombosis. Pia, wagonjwa 6 kutoka kundi la wasioitikia ambao hawakulazwa walielezea ugonjwa mkali zaidi kutokana na Covid-19 kuliko makundi ambayo yalitikia SSRI.
    </p>
   </sec>
  </sec>
  <sec id="Sec23" sec-type="discussion">
   <title>
    Majadiliano
   </title>
   <p id="Par44">
    Matokeo ya utafiti huu wa uchunguzi wa dodoso kuhusu athari za matibabu kwa kutumia SSRI katika PCS yanaonyesha kuwa SSRI inachangia kwa kiasi kikubwa kupunguza dalili za PCS. 63.4% (n = 95) ya wagonjwa waliripoti kupungua kwa dalili kwa kiwango cha kuridhisha hadi kikubwa na kuboreshwa kwa utendaji. Hii iliongeza ubora wa maisha inaweza kuchangia ushiriki wa kijamii. Wagonjwa wanne walikuwa wamepata unyogovu wa kliniki au shida ya wasiwasi wakati wa PCS. Matibabu kwa SSRI pia yaliondoa matatizo haya. Watu ambao walihisi kukata tamaa kutokana na PCS pia walihisi huzuni kidogo baada ya SSRI, lakini wote walihusisha hili na kupungua kwa dalili zao za PCS.
   </p>
   <p id="Par45">
    Maelezo ya usambazaji wa kijinsia usio sawa katika utafiti huu—pia uliopatikana katika utafiti mwingine wa PCS—huenda ni kwamba jeni nyingi za mfumo wa kinga ziko kwenye kromosomu ya X hivyo wanaume wana uwezekano mkubwa wa kuwa na maambukizi makali ya Covid-19, lakini wanawake wana uwezekano mkubwa wa kuwa na dalili kali zaidi za PCS zinazodumu kwa muda mrefu
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
     ,
     <xref ref-type="bibr" rid="CR49">
      49
     </xref>
    </sup>
    .
   </p>
   <p id="Par46">
    Kiwango cha juu cha elimu katika utafiti huu ikilinganishwa na tafiti nyingine kinaweza kuelezewa na uandikishaji wa wagonjwa kupitia LinkedIn. Uwiano mkubwa wa wagonjwa wa kike kutoka sekta ya afya na elimu unaweza kusababishwa na wingi wa wafanyakazi wa kike katika taaluma hizi kwenye mstari wa mbele wa janga. Zaidi ya hayo, walirudi kazini haraka baada ya maambukizi yao ya Covid-19 ambayo ni hatari kwa PCS
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Hatari nyingine nyingi za PCS katika utafiti huu zinakubaliana na makala ya mapitio ya Davis, kama vile: pumu, mzio, magonjwa ya tishu unganishi, virusi vya Epstein-Barr n.k. Ongezeko la kipekee kwa hatari zinazojulikana ni thrombophilia ya factor V Leiden. Katika utafiti huu, kulikuwa na wagonjwa wawili wenye tatizo hili la kuganda damu, wakati uwepo wake katika idadi ya watu kwa ujumla ni 1:5000
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
     <xref ref-type="bibr" rid="CR50">
      50
     </xref>
    </sup>
    . Wagonjwa wenye tatizo hili la kuganda damu wana hatari ya mara 80 zaidi ya kupata thrombosis.
   </p>
   <p id="Par47">
    Wagonjwa wote katika kundi letu (n = 95) walikuwa na uchovu wa muda mrefu wakati wa PCS ilhali katika utafiti wa Ujerumani ni wagonjwa 19/42 tu wa idadi ya watu wa PCS walioripoti uchovu wa muda mrefu kama katika ME/CFS. Maelezo ya tofauti hii yanaweza kuwa kwamba uchovu katika PCS huongezeka kwa muda. Wakati muda wa PCS katika utafiti wa Ujerumani ulikuwa miezi sita tu, katika utafiti wetu ulifikia wastani wa miezi 15. Pia, katika utafiti huu wa Ujerumani, kati ya wagonjwa wengine wa PCS bila uchovu wa muda mrefu (23/42), ni 15 tu walikuwa na upungufu wa neva au utambuzi. Katika utafiti wetu, 100% walikuwa na upungufu wa neva au utambuzi. Hata hivyo, dalili za neurocognitive huanza tu mwezi mmoja hadi miezi michache baada ya maambukizi ya Covid-19 na kuzidi kuwa mbaya kwa muda
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     <xref ref-type="bibr" rid="CR51">
      51
     </xref>
    </sup>
    .
   </p>
   <sec id="Sec24">
    <title>
     Nguvu na Udhaifu wa Utafiti
    </title>
    <p id="Par48">
     Hakuna dodoso zilizothibitishwa bado zinazopatikana kwa PCS. Hata hivyo, na ugonjwa mpya, ni muhimu kujifunza kuhusu dalili zote, kwa hivyo tulitumia dodoso iliyojumuisha maswali ya wazi. Hivyo, tuligundua kuwa dalili zinaweza kubadilika kwa muda. Dyspnoea na kupungua kwa harufu zinaonekana kupungua kwa muda, wakati uchovu na brainfog zinaonekana kuongezeka. Kupitia maswali ya wazi pia tuligundua dalili mpya, kama dalili za dissociative na kutoweza kutafuna vizuri.
    </p>
    <p id="Par49">
     Kutumia vyombo vitatu tofauti kuamua ufanisi wa matibabu ni nguvu zaidi ya utafiti huu. Kuna ushahidi thabiti wa uaminifu wa vipimo hivi. Alama ya Bell ni chombo kinachotumika sana katika utafiti wa uchovu wa muda mrefu, ingawa haijathibitishwa. Zaidi ya hayo, upimaji wa matokeo ya maswali ya wazi ulionekana kuwa wa kuaminika. Muhimu, vipimo vitatu vya athari vilihusiana kwa nguvu na kila mmoja, vikisaidia uaminifu wa vipimo vya mtu binafsi.
    </p>
    <p id="Par50">
     Udhaifu mkuu wa utafiti huu ni kwamba si jaribio la kudhibitiwa la nasibu (RCT). Hatukuwa na kundi la udhibiti. Kwa hivyo, athari ya placebo haiwezi kutengwa. Hata hivyo, inajulikana kuwa 85% ya wagonjwa ambao wana dalili miezi miwili baada ya maambukizi ya Covid-19 bado wanazo baada ya mwaka mmoja
     <sup>
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
     </sup>
     . ME/CFS na dysautonomia kawaida ni ya maisha yote
     <sup>
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
     </sup>
     . Kwa hivyo bila matibabu na SSRI, wagonjwa wengi wa PCS wanaweza kuteseka na hali hizi milele.
    </p>
    <p id="Par51">
     Na kuna ushahidi zaidi kwamba athari ya placebo inaweza isieleze kikamilifu matokeo mazuri. Athari ya placebo kawaida hutokea muda mfupi baada ya kuanza kwa uingiliaji na hupungua tena baada ya wiki chache, isipokuwa matarajio mazuri yatolewe tena
     <sup>
      <xref ref-type="bibr" rid="CR52">
       52
      </xref>
     </sup>
     . Hata hivyo, wagonjwa 72 (n = 95) bado hawakuwa na majibu katika wiki za kwanza, lakini badala yake walipata madhara. Wagonjwa 24 ambao walitumia SSRI kwa zaidi ya miezi sita waliripoti kuwa athari ilidumishwa, ingawa hawakuulizwa na sisi kufanya hivyo, kwani hatukuwa na uhusiano wa matibabu na wagonjwa. Utafiti wa kikundi bila kundi la udhibiti pia hauondoi kupona kwa asili. Hata hivyo, kwa sababu washiriki walikuwa wagonjwa sana kwa miaka 1.5 na walizorota kwa muda, inaonekana haiwezekani kwamba, kama wangepokea SSRI na kupona baada ya wiki chache, hii ingekuwa kutokana na kupona kwa asili.
    </p>
    <p id="Par52">
     Kufanya kazi na ripoti za kibinafsi daima kuna uwezekano wa upendeleo. Hata hivyo, ripoti za kibinafsi mara nyingi zinaonyesha uzoefu wa wagonjwa vizuri zaidi. Katika saikolojia si vigezo vyote vya kisaikolojia vinaweza kupimwa. Pia tuliwauliza wagonjwa kupima malalamiko yao kwenye kipimo cha 1 hadi 10. Kwa kuwaalika kulinganisha ukali wa malalamiko yao, tulianzisha muundo zaidi katika ripoti za kibinafsi.
    </p>
    <p id="Par53">
     Hatimaye, SSRIs za gharama ya chini zinagharamiwa na bima na hakuna gharama kwa mgonjwa, jambo ambalo linapinga athari ya placebo
     <sup>
      <xref ref-type="bibr" rid="CR53">
       53
      </xref>
     </sup>
     . Hata hivyo, uwezekano wa athari ya placebo unaweza tu kuondolewa kabisa na RCT.
    </p>
    <p id="Par54">
     Alama ya Bell kabla ya Covid-19/PCS na alama ya Bell wakati wa PCS kabla ya kuanza SSRI ilikamilishwa kwa kurudi nyuma na wagonjwa wote. Hii inaweza kuwa ilisababisha upendeleo fulani. Malalamiko ya PEM hayakuwa sehemu ya malalamiko 8 katika orodha ya alama; wagonjwa walipaswa kuorodhesha na kupima hili wao wenyewe chini ya "malalamiko mengine". Hii inaweza kuwa ilisababisha kuripotiwa kidogo kwa dalili hii muhimu. LinkedIn ilitoa uwakilishi mkubwa wa wagonjwa wenye kiwango cha juu cha elimu, lakini labda pia wa kundi la watu ambao awali walikuwa na afya na walikuwa wameajiriwa kikamilifu. Ni hasa katika kundi hili ambapo athari za PCS pamoja na matokeo ya SSRI yanaweza kuonekana vizuri.
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Njia Zingine za Utendaji za SSRIs katika PCS
    </title>
    <sec id="Sec26">
     <title>
      Kukosekana kwa Udhibiti wa Mfumo wa Tryptophan
     </title>
     <p id="Par55">
      Kwa kawaida njia ya catabolic kynurenine (KP) huvunja 95% ya amino asidi muhimu tryptophan ili kuzalisha cofactor muhimu ya nishati NAD+. Tryptophan iliyobaki hutumika kama mtangulizi wa serotonin na melatonin. (Tazama Fig.
      <xref ref-type="fig" rid="Fig6">
       6
      </xref>
      ). Mbali na NAD+, KP huzalisha metabolites tofauti: kynurenine, asidi ya kynurenic, 3OH-kynurenine, asidi ya quinolinic, asidi ya anthranilic na asidi ya 3OH-anthranilic. KP inachochewa na uvimbe na katika PCS inapatikana ikiwa imezidi
      <sup>
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
       ,
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      .
      <fig id="Fig6" position="float">
       <label>
        Figure 6
       </label>
       <caption xml:lang="en">
        <p>
         KP inayofanya kazi kupita kiasi inaathiri njia ya serotonini. Kipokezi cha aryl hydrocarbon (AHR) kina jukumu katika kudhibiti kinga na kusababisha usomaji wa enzyme ya indoleamine 2,3-dioxygenase (IDO-2). Kiasi cha IDO-2 katika PCS ni kingi na husababisha autophagy na kupungua kwa utendaji wa mitochondrial
         <sup>
          <xref ref-type="bibr" rid="CR28">
           28
          </xref>
         </sup>
         . Kwa sababu metabolites kynurenine na asidi ya kynurenine ni agonists wa kipokezi cha AHR, kuna 'mzunguko wa maoni chanya unaotoroka' unaozalisha metabolites zaidi na zaidi
         <sup>
          <xref ref-type="bibr" rid="CR28">
           28
          </xref>
          ,
          <xref ref-type="bibr" rid="CR30">
           30
          </xref>
          ,
          <xref ref-type="bibr" rid="CR31">
           31
          </xref>
          –
          <xref ref-type="bibr" rid="CR32">
           32
          </xref>
         </sup>
         . Baadhi ya metabolites ni sumu inayoweza kutokea. Kynurenine na mkazo wa oksidi huzuia enzyme tetrahydrobiopterin (BH4)
         <sup>
          <xref ref-type="bibr" rid="CR1">
           1
          </xref>
          ,
          <xref ref-type="bibr" rid="CR56">
           56
          </xref>
         </sup>
         , ikizuia njia zote za serotonini na dopamine
         <sup>
          <xref ref-type="bibr" rid="CR1">
           1
          </xref>
          ,
          <xref ref-type="bibr" rid="CR20">
           20
          </xref>
          ,
          <xref ref-type="bibr" rid="CR55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="CR56">
           56
          </xref>
         </sup>
         . Asidi ya kynurenic ni mpinzani wa kipokezi cha nikotini na mpinzani wa kipokezi cha glutaminergic
         <sup>
          <xref ref-type="bibr" rid="CR28">
           28
          </xref>
          ,
          <xref ref-type="bibr" rid="CR30">
           30
          </xref>
          ,
          <xref ref-type="bibr" rid="CR32">
           32
          </xref>
         </sup>
         . Asidi ya quinolinic huzuia kipokezi cha glutaminergic
         <sup>
          <xref ref-type="bibr" rid="CR28">
           28
          </xref>
         </sup>
         . Tunapotaka kuingilia kati: njia ya kynurenine inaweza kuzuiwa kwa njia mbalimbali na njia ya serotonini inaweza kuchochewa kwa njia mbalimbali. Kuingilia kati kupitia SSRI imekuwa muhimu zaidi hadi sasa.
        </p>
       </caption>
       <graphic href="/ProjectMundo/MediaObjects/10X1038_s41598-023-45072-9/41598_2023_45072_Fig6_HTML.png" id="MO6" mime-subtype="PNG" specific-use="web"/>
      </fig>
     </p>
     <p id="Par56">
      KP iliyozidi inachukua zaidi ya 95% ya tryptophan katika PCS. Utafiti unaonyesha kuwa kiasi cha tryptophan katika damu kimepungua kwa wagonjwa wa PCS
      <sup>
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . Upungufu wa tryptophan labda tayari upo wakati wa maambukizi ya Covid-19, kwa sababu Covid-19 inajishikiza na protini zake za spike kwenye vipokezi vya Angiotensin Converting Enzyme (ACE2) kwenye matumbo, wakati tryptophan pia hutumia kipokezi hicho hicho kufyonzwa kutoka matumboni
      <sup>
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
      </sup>
      . Kuna uhusiano mkubwa kati ya kiwango cha metabolites katika damu na ukali wa upungufu wa utambuzi katika PCS, (
      <italic>
       p
      </italic>
      &lt; 0.001)
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
      </sup>
      . KP kwa kawaida ina vipengele vya neurotoxic na neuroprotective. Hata hivyo, KP iliyozidi wakati wa maambukizi makali, ni sumu kwa neurons, hasa kwa neurons za serotonin. Sio tu kwamba KP inachukua tryptophan kutoka kwenye njia ya serotonin, metabolite kynurenine na mkazo wa oksidi pia hupunguza kiwango cha tetrahydrobiopterin (BH4), coenzyme muhimu ya njia ya serotonin. Zaidi ya hayo, BH4 ni coenzyme muhimu ya njia ya dopamine—na kwa njia ya norepinephrine—hivyo KP iliyozidi inaharibu mifumo hii miwili ya neurotransmitter pia. Wakati hakuna tena tryptophan ya kutosha, hii inaweza kusababisha upungufu wa serotonin
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      .
     </p>
     <p id="Par57">
      SSRI hufanya serotonini katika neuroni kupatikana zaidi kupitia kuzuia urejeshaji na inaweza kwa kiasi fulani kufidia upungufu wa tryptophan
      <sup>
       <xref ref-type="bibr" rid="CR57">
        57
       </xref>
      </sup>
      . Zaidi ya hayo, SSRIs hupunguza msongo wa oksidativi
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
      </sup>
      . Hii inaweza kuwa maelezo ya matokeo yetu kwamba wagonjwa wa PCS mara nyingi wana malalamiko machache kutokana na SSRIs. Lakini hiyo inaweza kuisha wakati serotonini yote kutoka kwa neuroni ipo kwenye sinapsi. Hata hivyo, baada ya nusu mwaka au zaidi (katika utafiti huu wagonjwa 24), watu wengi bado walihisi vizuri walipotumia SSRI. Kwa hivyo tunaweza (kihypothetiki) kuhitimisha kwamba SSRI labda inachangia kwa njia isiyo ya moja kwa moja—wakati kuna upungufu wa serotonini katika neuroni—kwamba neuroni hizi zinaanza kuvuta zaidi tryptophan inayopatikana. Kwa hivyo SSRIs zinaweza kupunguza kasi ya KP inayofanya kazi kupita kiasi. Hakuna hoja ya kinadharia dhidi ya dhana hii
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      .
     </p>
     <p id="Par58">
      Lakini kuna njia zaidi za utafiti wa baadaye kuendeleza mstari huu wa utafiti wa kliniki unaotegemea metaboli ya tryptophan. Uonyeshaji wa IDO2 unaweza kusimamishwa na mpinzani wa AHR, kama vile kirutubisho cha lishe resveratrol au dawa ya majaribio ya saratani IK-175
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
      </sup>
      . Zaidi ya hayo, kynurenine ni wapinzani wa kipokezi cha glutaminergic na asidi ya quinolinic hata inazuia kipokezi hiki
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
      </sup>
      . N-acetylcysteine (NAC) haitoi tu antioxidant glutathione, lakini pia ni agonisti wa kipokezi cha glutaminergic
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
      </sup>
      . Asidi ya quinolinic yenye sumu na asidi ya kynurenine ni wapinzani wa kipokezi cha nicotinic. Nikotini ni agonisti wa kipokezi cha nicotinic. Kutumia viraka vya nikotini husaidia wagonjwa wa PCS. Hii inaweza kuwa sio tu kwa sababu nikotini ni agonisti wa kipokezi cha nicotinic na kwa hivyo mpinzani wa metabolites hizi zenye sumu, lakini nikotini pia ni agonisti wa acetylcholine (ACh) yenye nguvu
      <sup>
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
      </sup>
      . ACh ni neurotransmita muhimu zaidi katika misuli. Zaidi ya hayo, asidi ya foliki (vit. B11) inaweza kukuza ubadilishaji wa B2 kurudi kuwa B4 kwa manufaa ya njia ya serotonini na dopamine
      <sup>
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec27">
     <title>
      Uharibifu wa Mhimili wa HPA
     </title>
     <p id="Par59">
      Baada ya tukio la msongo, hypothalamus hutoa homoni ya kutolewa kwa corticotropin (CRH), ambayo husababisha tezi ya pituitari kutoa homoni ya adrenocorticotropic (ACTH), ambayo nayo husababisha glucocorticoids (GCs) kutolewa na gamba la adrenal.
     </p>
     <p id="Par60">
      Katika PCS viwango vya cortisol (glucocorticoids) vilikuwa kwa wastani vimepungua kwa nusu
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      . Hiyo ni dalili kwamba mhimili wa HPA umevurugika
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      . Kwa kulinganisha, katika ME/CFS, mhimili wa HPA umevurugika kidogo
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      . GCs zinazotolewa na tezi za adrenal, hufanya kazi kwenye karibu aina zote za seli za kinga na hufanya kazi za wazi za kukandamiza kinga na kupunguza uvimbe
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      . SSRIs huathiri mhimili wa HPA
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Kwa mfano kwa kuongeza msongamano wa kipokezi cha GC katika hypothalamus na hippocampus (kituo cha udhibiti wa kumbukumbu). Zaidi ya hayo, utoaji wa papo hapo wa ligands za kipokezi cha 5-HTP uliongeza viwango vya plasma vya ACTH na cortisol kwa wanyama na wanadamu
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      . Lakini athari sio ya mwelekeo mmoja. Kwa mfano: kwa wagonjwa wenye unyogovu mkubwa na viwango vya juu vya cortisol, SSRI hupunguza kiwango cha cortisol lakini husababisha majibu ya juu ya Cortisol Awaking Response (CAR)
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      . Katika ME/CFS, SSRI hufanya kazi kwa wastani kwa theluthi moja tu ya wagonjwa
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      . SSRIs zinaonekana kufanya kazi vizuri zaidi katika PCS kuliko katika ME/CFS. Hii inaweza kuwa dalili kwamba SSRIs ni (kwa sehemu) zinafaa katika PCS kwa kuathiri mhimili huu wa homoni. Dalili nyingine ya dhana hii ni ripoti yetu ya mgonjwa ambaye alipewa hydrocortisone kwa sababu PCS ilisababisha tezi yake ya adrenal pekee inayofanya kazi kushindwa, lakini ambaye alipona na SSRI, baada ya hapo aliweza kupunguza hydrocortisone. Katika mgonjwa huyu, SSRI inaonekana kurejesha sio tu mhimili wa HPA, lakini pia mhimili wa hypothalamic-pituitary-thyroid ulioharibika
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      . Swali ni ikiwa—mbali na mhimili wa HPA—mhimili zaidi wa homoni unaoanzia kwenye hypothalamus umevurugwa na Covid-19/PCS. Hivyo, mabadiliko yaliyoripotiwa katika mzunguko wa hedhi baada ya Covid-19 yanaweza pia kutokana na mhimili wa hypothalamic-pituitary–gonadal ulioharibika
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec28">
     <title>
      Uharibifu wa Shina la Ubongo
     </title>
     <p id="Par61">
      Shina la ubongo, sehemu ya zamani zaidi ya ubongo wetu, inawajibika kwa kazi za msingi kama vile joto la mwili, mdundo wa usingizi-kuamka, kiwango cha moyo, kupumua, shinikizo la damu, usagaji chakula, harakati za macho, kukojoa, kusikia, kuonja, kutafuna, kumeza, na kuhisi harakati na mvuto. Neurotransmita ambazo ni muhimu sana hapo ni pamoja na serotonini, norepinephrine na dopamine
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      . Neuroni za serotonergic zinaanza katika nuclei ya raphe katika pons na zinaweza kuathiri hapo
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      .
     </p>
     <p id="Par62">
      Virusi vya Covid-19 vinaingia kwenye seli za shina za ubongo kwa urahisi kwa kujishikiza kwenye vipokezi vingi vya ACE2
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
      </sup>
      . Maeneo yenye hypometabolic katika pons yalipatikana katika utafiti wa wagonjwa watatu wa PCS. Kawaida, SSRIs huongeza ubora wa usingizi, ingawa, si kila wakati
      <sup>
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      . Katika utafiti huu, wagonjwa 29 waliripoti katika swali la wazi kwamba usingizi wao uliimarika walipotumia SSRI. Hii inaweza kuelezewa na ushawishi wa SSRI kwenye shina la ubongo. Lakini hii inaweza kuwa si sababu pekee inayofanya wagonjwa kulala vizuri zaidi. Tuliona katika Fig.
      <xref ref-type="fig" rid="Fig6">
       6
      </xref>
      kwamba homoni ya usingizi melatonin inatokana na serotonini. Wakati neuroni za serotonini zinapochukua zaidi kutoka kwa tryptophan inayopatikana, melatonin zaidi inaweza kuzalishwa pamoja na serotonini zaidi. Kupungua kwa mapigo ya moyo, upungufu wa pumzi, malalamiko ya njia ya utumbo, udhibiti bora wa joto (mgonjwa mmoja) na uwezo wa kutafuna vizuri zaidi (mgonjwa mmoja) pia inasaidia wazo kwamba SSRIs zinaweza (kwa sehemu) kurejesha mifumo ya neurotransmitter iliyovurugika katika shina la ubongo.
     </p>
    </sec>
    <sec id="Sec29">
     <title>
      Usawa wa Mfumo wa Neva wa Uhuru (ANS) Ulioharibika
     </title>
     <p id="Par63">
      Dysautonomia, hasa POTS, mara nyingi ni dalili ya PCS. Picha ya kliniki yenye alama ya Bell ya 20 au chini (karibu nusu ya wagonjwa katika utafiti huu) ni ya kushangaza, kama inavyoonyeshwa na majibu ya maswali ya wazi: wagonjwa waliochoka na mapigo ya moyo wakiwa wamelala kwenye kochi. Katika hali hii, shina la ubongo linaonyesha msisimko mkubwa na linaonekana kuwa katika hali ya 'fight-or-flight' pamoja na mfumo wa neva wa huruma
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
      </sup>
      . Huu ni utaratibu wa kimsingi wa kuishi mbele ya hatari, ambapo ANS ya huruma inatawala. Jibu la 'fight-or-flight' huamsha mhimili wa HPA ili cortisol ya ziada itolewe na glukosi itolewe kwenye misuli kwa ajili ya hatua
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
      </sup>
      . Badala yake, viwango vya cortisol vilivyopimwa kwa wagonjwa wa PCS ni wastani wa 50% ya kawaida na misuli ni dhaifu badala ya kuwa tayari kusinyaa. Udhaifu wa misuli sio tu kwa sababu hakuna glukosi inayotolewa kwenye misuli. Pia ni kwa sababu PCS inahusishwa na kingamwili dhidi ya kipokezi cha adrenergic kilichounganishwa na protini ya G na kipokezi cha muscarinic acetylcholine
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
      </sup>
      . Acetylcholine ni neurotransmitter kuu inayosababisha misuli kusonga.
     </p>
     <p id="Par64">
      Nerve ya vagus ya ANS (parasympathetic) pia inatoka kwenye pons katika shina la ubongo. Lakini nerve hii—kama misuli—hutumia acetylcholine kama neurotransmitter, hivyo SSRI haiwezi kuingilia hapo. Mtu huzungumza juu ya nerve ya vagus iliyopooza, labda kwa sababu ya kingamwili dhidi ya kipokezi cha muscarinic acetylcholine
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . ANS ya huruma inatawala juu ya ANS ya parasympathetic katika PCS, wakati kingamwili dhidi ya kipokezi cha adrenergic kilichounganishwa na protini ya G pia zipo. Labda njia ya (nor)epinephrine ina matatizo machache na KP inayofanya kazi kupita kiasi, kwa sababu haitumii tryptophan kama mtangulizi, bali phenylalanine. SSRIs mara nyingi huonekana kupunguza POTS na mapigo ya moyo. Hii haihusiani na kuzuia kuchukuliwa tena kwa serotonini, kwani serotonini haiathiri ANS. Kuzuia kuchukuliwa tena kwa norepinephrine kunaweza kupunguza POTS, lakini kinadharia kunaweza kusababisha mapigo ya moyo. Kupungua kwa mapigo ya moyo lazima kupatikane katika utaratibu mwingine, kama vile ushawishi wa SSRIs kwenye gamba la cingulate la mbele (ACC) katika ubongo
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec30">
     <title>
      Dalili za CNS
     </title>
     <p id="Par65">
      Brainfog na mzigo wa hisia ulijibu vizuri zaidi kwa matibabu na SSRI. Nuclei ya raphe (pons) katika shina la ubongo ni eneo la asili ya mfumo wa serotonini. Kutoka hapo, axons hutumwa kote CNS
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      . Kwa hivyo SSRIs zinaweza kuingilia kati katika ubongo mzima.
     </p>
     <p id="Par66">
      Dalili za kutengana pia zilipotea. Katika mzigo wa hisia na kutengana, kuna mzigo wa hisia kutokana na ukosefu wa kuchuja. Maeneo ya msingi ya hisia za unimodal hayashirikiani vizuri na maeneo ya hisia za kiunganishi
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
      </sup>
      . Inajulikana kwamba SSRI inaweza kusaidia wakati mwingine katika hili
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      .
     </p>
     <p id="Par67">
      Wagonjwa wengi wa PCS wanakumbana na tatizo la kusahau
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . Katika hippocampus, kituo cha udhibiti wa kumbukumbu, neuroni za serotonergic zinatawala. SSRIs pia huchochea uzalishaji wa seli za serotonini katika hippocampus
      <sup>
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
      </sup>
      . Inawezekana kwa sehemu kutokana na hili, kusahau kwa wagonjwa kulipungua.
     </p>
    </sec>
    <sec id="Sec31">
     <title>
      Agonisti ya Kipokezi cha Sigma1
     </title>
     <p id="Par68">
      SSRIs fluvoxamine na fluoxetine zimeonyeshwa kuwa na athari za ziada za kupunguza uchochezi wakati wa maambukizi ya Covid-19 kwa kuzuia sphingomyelinase acid (ASM)
      <sup>
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
      </sup>
      . Zaidi ya hayo, SSRI hupunguza cytokines za pro-inflammatory Interleukin 2 (IL 2) na IL 17 katika CNS. Katika kesi hii, SSRI lazima iwe agonist ya kipokezi cha sigma1. Kipokezi hiki cha opioid kinahusika miongoni mwa mengine katika kupunguza urudufishaji wa virusi na kuzuia uanzishaji upya wa virusi vya herpes kama vile Epstein-Barr Virus (EBV) na msongo wa endoplasmic reticulum (ER) na uchochezi
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      . Tulipendekeza tu SSRIs ambazo ni agonists za kipokezi cha sigma1
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       ,
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      . Mgonjwa mmoja alipewa sertraline na daktari wa familia, bila majibu. Baada ya kubadilisha hadi citalopram, alijibu kwa kiasi kizuri. Kwa wagonjwa wengine watano, madaktari wa familia waliagiza antagonists za kipokezi cha sigma1 sertraline (n = 4) au paroxetine (n = 1). Wagonjwa hawa watano waliripoti maboresho mazuri (n = 2), maboresho ya kiasi kizuri (n = 2) au maboresho ya wastani (n = 1). Hakukuwa na ushahidi wa kuunga mkono au kupinga tofauti katika athari iliyopimwa na swali la wazi kulingana na kama wagonjwa walipokea agonists au antagonists za sigma1 (BF = 0.43). Ikiwa tunajumuisha mgonjwa aliyebadilisha kutoka sertraline (hakuna athari) hadi citalopram (athari ya kiasi kizuri), hakuna tofauti kubwa inayobaki (BF = 0.39). Hii ni ushahidi wa hadithi tu kwamba utaratibu kupitia kipokezi cha sigma1 unachukua jukumu katika hatua ya SSRI katika PCS. Hata hivyo, kundi linalotumia antagonist ya sigma1 katika utafiti huu ni dogo sana kwa uchambuzi sahihi wa takwimu.
     </p>
    </sec>
    <sec id="Sec32">
     <title>
      Ushawishi Chanya wa SSRIs kwenye Mfumo wa Mzunguko
     </title>
     <p id="Par69">
      Wagonjwa wengi wa Covid-19 na PCS wana microclots zinazoashiria matatizo ya kuganda kwa damu. Microclots huzuia mtiririko wa oksijeni na virutubisho kwa viungo na tishu
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
      </sup>
      . Platelets zinahusika katika kuganda kwa damu. Platelets husafirisha serotonini, kwa sababu serotonini ina kazi katika kuganda kwa damu. Kwa upungufu wa serotonini, platelets zinakuwa na ufanisi mdogo. Kwa sababu SSRIs huzuia urejeaji wa serotonini katika platelets, huongeza muda wa kuganda na inaweza kinadharia kufuta microclots
      <sup>
       <xref ref-type="bibr" rid="CR75">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
      </sup>
      . Wagonjwa wawili wenye thrombophilia ya factor V Leiden walijibu vizuri na kwa wastani, mtawalia. Hii inaweza kumaanisha kuwa athari ya anticoagulant ya SSRIs—ikidhani kuwa microclots zilicheza jukumu kwa wagonjwa hawa—inaweza kuchangia katika majibu yao. Ikiwa itathibitishwa kuwa PCS ni ya kawaida zaidi katika thrombophilia ya factor V Leiden, ugonjwa huu wa kuganda unapaswa kuongezwa kwenye orodha ya sababu za hatari.
     </p>
     <p id="Par70">
      Lakini SSRI inaweza kufaidisha mzunguko wa damu kwa njia nyingine pia. Inaweza kuonyesha athari ya kupunguza uchochezi kwenye seli za endothelial. SSRIs hupunguza usemi wa cytokine-induced endothelial adhesion. Hii inafanya kuwa vigumu kwa molekuli za adhesion zinazozunguka, kama vile monocytes, kushikamana
      <sup>
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
      </sup>
      . Utaratibu huu unaweza kueleza kwa sehemu athari zao za kulinda moyo
      <sup>
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
      </sup>
      .
     </p>
    </sec>
   </sec>
   <sec id="Sec33">
    <title>
     Kikundi Kidogo chenye Fibromyalgia
    </title>
    <p id="Par71">
     Maumivu ya misuli na udhaifu yalipungua kidogo zaidi katika kundi zima (n = 95). Tunaona pia hili kwa wagonjwa wenye fibromyalgia (n = 5) ambao waliripoti maboresho kidogo au hakuna baada ya kutumia SSRI.
    </p>
   </sec>
   <sec id="Sec34">
    <title>
     Wasiotikia
    </title>
    <p id="Par72">
     Kikundi cha wasioitikia (n = 9) walikuwa wagonjwa zaidi na maambukizi ya Covid-19 kuliko wale waliotoa majibu mazuri kwa SSRIs. Inawezekana kwamba mfululizo wa uchochezi mkali uliosababishwa na Covid-19 katika CNS ulitoa histamini nyingi. Vipokezi vya histamini vya kuzuia hupunguza serotonini katika CNS, na kuzuia SSRI kutoa serotonini ya nje kwa ufanisi
     <sup>
      <xref ref-type="bibr" rid="CR78">
       78
      </xref>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . Kwa kuongeza wapinzani wa Histamine1 na 2 kwenye matibabu, SSRI inaweza kimsingi kuwa na ufanisi
     <sup>
      <xref ref-type="bibr" rid="CR40">
       40
      </xref>
     </sup>
     . Hata hivyo, ukosefu wa majibu kwa SSRI unaweza pia kuwa umesababishwa na sababu kubwa: yaani, neuropathology inayofanana na ugonjwa wa Alzheimer imepatikana katika maambukizi ya Covid-19. Katika CNS, mkusanyiko wa β-amyloid, uundaji wa plaque, tauopathy na kifo cha seli vimeelezewa
     <sup>
      <xref ref-type="bibr" rid="CR79">
       79
      </xref>
     </sup>
     . Katika hali hizi, SSRI haiwezi tena kuwa na ufanisi.
    </p>
   </sec>
   <sec id="Sec35">
    <title>
     Lini SSRI Inapaswa Kusitishwa?
    </title>
    <p id="Par73">
     Dhana yetu ni kwamba kwa dalili nyingi za PCS, mifumo ya neurotransmitter haijaharibika bali imevurugika na ina uwezekano mkubwa wa kukosa tryptophan kutokana na KP inayofanya kazi kupita kiasi. Lakini baada ya mchakato wa muda mrefu wa PCS unaodumu miaka miwili, SSRIs haziwezi kutarajiwa "kurekebisha" mifumo hii kwa muda mfupi mradi njia ya kynurenine bado inafanya kazi kupita kiasi. Kwa kulinganisha, muda wa matibabu kwa unyogovu wa awali ni miezi sita hadi mwaka mmoja na kwa unyogovu unaorudiwa kawaida angalau miaka 3
     <sup>
      <xref ref-type="bibr" rid="CR80">
       80
      </xref>
     </sup>
     . Katika ugonjwa wa depersonalization unaosababishwa na dawa za sumu, wakati mwingine miaka 6 ya matibabu inapendekezwa (uzoefu wa kliniki wa mwandishi wa kwanza)
     <sup>
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
     </sup>
     . Ugonjwa wa depersonalization unaosababishwa na dawa ni sawa kifenomenolojia na PCS, ukiondoa uchovu na maumivu ya misuli. Uchaguzi duni wa vichocheo, mzigo wa hisia, derealization na brainfog ni sawa katika hali hizo mbili. Mapendekezo ya awali ni kuendelea na matibabu kwa SSRI kwa angalau miaka 1.5—2. Utafiti zaidi unahitajika ili kuunga mkono dhana yetu kuhusu kurekebisha mifumo ya neurotransmitter na SSRIs. Uwezekano mwingine unaweza kuwa kwamba SSRIs zinakandamiza tu dalili kwa sababu ya upungufu wa tryptophan. Kinyume na hili ni uzoefu wa wagonjwa wawili (wa kwanza akiwa na alama ya chini sana ya Bell ya 20 mwanzoni mwa matibabu ya SSRI) ambao waliacha SSRI baada ya miezi 8 na mwaka mmoja, mtawalia, kwa sababu walihisi kuwa na afya kabisa kwa miezi 2 na 7, mtawalia. Wanaendelea kufanya vizuri (miezi saba na minne baada ya kusitisha). Hata hivyo, wagonjwa wengi wanataja kwamba, licha ya majibu mazuri kwa SSRI, wanapaswa kuwa waangalifu wasivuke mipaka yao. PEM ilikuwa imepungua sana, lakini kwa shughuli nyingi mfululizo, kurudi nyuma—ingawa ni fupi na si kali kama awali—kunaweza kufuata.
    </p>
   </sec>
  </sec>
  <sec id="Sec36" sec-type="conclusions">
   <title>
    Hitimisho
   </title>
   <p id="Par74">
    Utafiti huu wa kwanza wa dodoso la uchunguzi wa SSRIs kwa wagonjwa wa PCS unaonyesha kwamba matibabu haya yanaweza kuchangia kupunguza dalili kwa kiasi kikubwa, hasa brainfog na mzigo wa hisia. Uchovu, POTS, mapigo ya moyo, PEM na utendaji wa jumla pia viliboreshwa kwa kiasi kikubwa. Kwa kukosekana kwa utafiti mwingine wowote uliokamilika juu ya matibabu ya dawa yenye ufanisi ya PCS, huu ni matokeo yenye maana
    <bold>
     .
    </bold>
    Ikiwa itathibitishwa zaidi, hii inaweza kuwa na athari muhimu kwa mtu binafsi na jamii.
   </p>
   <p id="Par75">
    Tuliunda mifumo saba inayowezekana ya kuelezea ya neurobiolojia kulingana na fasihi ya hivi karibuni juu ya PCS iliyojumuishwa na maarifa yaliyopo tayari. Ushahidi wa kliniki kwa mifumo mitano kati ya saba inayowezekana ya kuelezea ya SSRI katika PCS ilipatikana katika utafiti huu. Hizo ni ushawishi kwenye mhimili wa HPA, shina la ubongo, ANS, CNS na ushawishi kwenye mfumo wa mzunguko. Kuvurugika kwa mfumo wa tryptophan kunaweza kuwa muundo mkuu wa biokemia unaoelezea kwa kiasi kikubwa mifumo hii mitano.
   </p>
   <p id="Par76">
    Pengine utaratibu ambao agonists wa kipokezi cha sigma1 wanaweza kuzuia urudufishaji wa virusi unaweza pia kufanya kazi, lakini kikundi kilichotumia mpinzani wa kipokezi cha sigma1 kilikuwa kidogo sana kulinganisha na kikundi kikubwa kilichotumia agonist wa sigma1 na tulipata ushahidi wa hadithi tu kwa hilo.
   </p>
   <p id="Par77">
    Inawezekana ni mchanganyiko wa idadi ya mifumo ambayo SSRI inafanya kazi kwa ufanisi katika PCS. Mifumo hiyo ni sehemu tu sawa na ile inayodhaniwa kuwa inawajibika kwa kuboresha unyogovu au matatizo ya wasiwasi.
   </p>
   <p id="Par78">
    Utafiti wa RCT na SSRIs kwa wagonjwa wa PCS unabaki kuwa ufuatiliaji wa haraka kwa utafiti huu. Katika RCT hiyo, kipimo cha juu cha SSRI kinapaswa kuthibitishwa. Tunatambua kuwa kipimo hiki, kulingana na majibu ya mtu binafsi na madhara, ni vigumu kuunganisha na RCT. Suluhisho za vitendo zinapaswa kupatikana kama kuunda wasifu wa pharmacogenetic mapema, kwa sababu watu wengi huvunja baadhi ya SSRIs vibaya. Utafiti huo pia unaweza kuamua alama za kibayolojia kama vile cortisol, kuganda, metabolites za KP na cytokines zilizoinuliwa katika PCS, kabla na wakati wa matumizi ya SSRI. Vipimo vinavyopendekezwa ni wiki 4 hadi 6 baada ya kuanza na baada ya miezi 3 hadi 6 wakati wa matumizi ya SSRI.
   </p>
   <p id="Par79">
    Katika PCS, makundi tofauti ya wagonjwa yanatofautishwa
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Makundi haya yanashirikiana kwa sehemu: uchovu sugu, PEM, malalamiko ya utambuzi, MCAS, POTS, matatizo ya misuli n.k. Kwa utafiti wa ziada, ni muhimu kupata ufafanuzi zaidi kwa makundi gani ya wagonjwa dawa za SSRI zinafanya kazi vizuri zaidi.
   </p>
   <p id="Par80">
    Zaidi ya hayo, itakuwa muhimu kulinganisha kundi moja linalopokea SSRI ambayo ni agonist ya kipokezi cha sigma1 na kundi lingine linalopokea SSRI ambayo ni antagonist ya kipokezi cha sigma1. Pia, ushawishi wa baadhi ya virutubisho na dawa kama NAC, resveratrol, IK-175, asidi ya foliki, plasta za nikotini—iwe zimeongezwa kwenye SSRI au la—unaweza kuchunguzwa
    <sup>
     <xref ref-type="bibr" rid="CR61">
      61
     </xref>
     <xref ref-type="bibr" rid="CR59">
      59
     </xref>
     <xref ref-type="bibr" rid="CR60">
      60
     </xref>
     <xref ref-type="bibr" rid="CR63">
      63
     </xref>
     <xref ref-type="bibr" rid="CR62">
      62
     </xref>
    </sup>
    .
   </p>
   <p id="Par81">
    Kwa kuzingatia matokeo makubwa ya kibinafsi, kijamii na kiuchumi ya PCS, utafiti zaidi ni wa umuhimu mkubwa.
   </p>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Shukrani
   </title>
   <p>
    Tunamshukuru Willem Pieters, Lous Rijssenberg, Hans in 't Veen na Dick Swaab kwa maoni yao muhimu juu ya toleo la awali la maandiko. Tunamshukuru Dora Wynchank kwa kutafsiri maandiko. Tunamshukuru Kim Caarls na Rik Linssen kwa kupima swali la wazi. Na mwisho lakini sio kwa umuhimu mdogo, tunawashukuru wagonjwa wote wa PCS kwa kutupa uzoefu wao wa kutumia SSRI.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Mchango wa waandishi
   </title>
   <p>
    Uundaji wa dhana: C.P.R.; Kuwajulisha na kuwaongoza wagonjwa na madaktari wa jumla: C.P.R. na I.N.; Usimamizi wa taarifa mtandaoni kwenye sepsis-en-daarna.nl: I.N.; Dodoso za awali na orodha za Bell: C.P.R. na I.N.; Usindikaji wa dodoso na orodha za Bell, uingizaji wa data na usimamizi: E.K.d.V.; Uchambuzi na uwasilishaji: I.E.J.d.V.; Uandishi: C.P.R.; Uhariri: E.K.d.V. na J.J.S.K.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Upatikanaji wa Takwimu
   </title>
   <p>
    The data files and the instruments used are available from the first author.
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar1" sec-type="COI-statement">
    <title>
     Maslahi Yanayokinzana
    </title>
    <p id="Par82">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Marejeleo
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Davis
        </surname>
        <given-names>
         HE
        </given-names>
       </name>
       <name>
        <surname>
         McCorkell
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Vogel
        </surname>
        <given-names>
         JM
        </given-names>
       </name>
       <name>
        <surname>
         Topol
        </surname>
        <given-names>
         EJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Long COVID: Major findings, mechanisms and recommendations
      </article-title>
      <source>
       Nat. Rev. Microbiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       21
      </volume>
      <fpage>
       133
      </fpage>
      <lpage>
       146
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhtV2rtrw%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36639608
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9839201
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41579-022-00846-2
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023.
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023">
       https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023
      </ext-link>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="other">
      Bach, K. New data shows long Covid is keeping as many as 4 million people out of work.
      <ext-link ext-link-type="uri" xlink:href="https://www.brookings.edu/articles/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/">
       https://www.brookings.edu/articles/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="other">
      Fogoros, R. N. What Is Tilt Table Testing? What to expect when undergoing this test.
      <ext-link ext-link-type="uri" xlink:href="https://www.verywellhealth.com/tilt-table-testing-1745418">
       https://www.verywellhealth.com/tilt-table-testing-1745418
      </ext-link>
      (2022).
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Oaklander
        </surname>
        <given-names>
         AL
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Peripheral neuropathy evaluations of patients with prolonged long COVID
      </article-title>
      <source>
       Neurol. Neuroimmunol. Neuroinflamm.
      </source>
      <year>
       2022
      </year>
      <volume>
       9
      </volume>
      <fpage>
       e1146
      </fpage>
      <pub-id pub-id-type="pmid">
       35232750
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8889896
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1212/NXI.0000000000001146
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Queiroz
        </surname>
        <given-names>
         MAF
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome
      </article-title>
      <source>
       Front Cell Infect. Microbiol.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <fpage>
       922422
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xitl2rsbfJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       35846757
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9279918
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fcimb.2022.922422
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Spudich
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Nath
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Nervous system consequences of COVID-19
      </article-title>
      <source>
       Science
      </source>
      <year>
       2022
      </year>
      <volume>
       1979
      </volume>
      <issue>
       375
      </issue>
      <fpage>
       267
      </fpage>
      <lpage>
       269
      </lpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022Sci...375..267S
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1126/science.abm2052
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Monje
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Iwasaki
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The neurobiology of long COVID
      </article-title>
      <source>
       Neuron
      </source>
      <year>
       2022
      </year>
      <volume>
       110
      </volume>
      <fpage>
       3484
      </fpage>
      <lpage>
       3496
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XislWht7zN
      </pub-id>
      <pub-id pub-id-type="pmid">
       36288726
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9537254
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.neuron.2022.10.006
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hugon
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cognitive decline and brainstem hypometabolism in long COVID: A case series
      </article-title>
      <source>
       Brain Behav.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <fpage>
       e2513
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvF2msbnJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       35290729
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9014998
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/brb3.2513
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Saper
        </surname>
        <given-names>
         CB
        </given-names>
       </name>
       <name>
        <surname>
         Elmquist
        </surname>
        <given-names>
         JK
        </given-names>
       </name>
      </person-group>
      <person-group person-group-type="editor">
       <name>
        <surname>
         Kandel
        </surname>
        <given-names>
         ER
        </given-names>
       </name>
       <name>
        <surname>
         Koester
        </surname>
        <given-names>
         JD
        </given-names>
       </name>
       <name>
        <surname>
         Mack
        </surname>
        <given-names>
         SH
        </given-names>
       </name>
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         SA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The brain stem
      </article-title>
      <source>
       Principels Of Neural Sciences
      </source>
      <year>
       2020
      </year>
      <publisher-name>
       The McGraw-Hill Companies
      </publisher-name>
      <fpage>
       996
      </fpage>
      <lpage>
       999
      </lpage>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kedor
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       5104
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.5104K
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XitlSnt7bE
      </pub-id>
      <pub-id pub-id-type="pmid">
       36042189
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9426365
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-022-32507-6
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hornig
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome
      </article-title>
      <source>
       Mol. Psychiatry
      </source>
      <year>
       2016
      </year>
      <volume>
       21
      </volume>
      <fpage>
       261
      </fpage>
      <lpage>
       269
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2MXlsFektbY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       25824300
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/mp.2015.29
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Morris
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Maes
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Hypothalamic-pituitary-adrenal hypofunction in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) as a consequence of activated immune-inflammatory and oxidative and nitrosative pathways
      </article-title>
      <source>
       Mol. Neurobiol.
      </source>
      <year>
       2017
      </year>
      <volume>
       54
      </volume>
      <fpage>
       6806
      </fpage>
      <lpage>
       6819
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28XhslSmtL7F
      </pub-id>
      <pub-id pub-id-type="pmid">
       27766535
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s12035-016-0170-2
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lowell
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Swanson
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Hro
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <person-group person-group-type="editor">
       <name>
        <surname>
         Kandel
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         Koester
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Mack
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The hypothalamus: Autonomic, hormonal, and behavioral control of survival
      </article-title>
      <source>
       Principles of Neural Science
      </source>
      <year>
       2020
      </year>
      <publisher-loc>
       London
      </publisher-loc>
      <publisher-name>
       The McGraw-Hill Company
      </publisher-name>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Jacobs
        </surname>
        <given-names>
         GE
        </given-names>
       </name>
      </person-group>
      <source>
       Pharmacological Aspects of Corticotrophinergic and Vasopressinergic Function Test for HPA Axis Activation
      </source>
      <year>
       2010
      </year>
      <publisher-name>
       Leiden University
      </publisher-name>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="other">
      Bao, A.-M., Ruhé, H. G., Gao, S.-F. &amp; Swaab, D. F. Neurotransmitters and neuropeptides in depression. 107–136 (2012).
      <ext-link ext-link-type="doi" xlink:href="10.1016/B978-0-444-52002-9.00008-5">
       https://doi.org/10.1016/B978-0-444-52002-9.00008-5
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ruhé
        </surname>
        <given-names>
         HG
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major depressive disorder
      </article-title>
      <source>
       Psychoneuroendocrinology
      </source>
      <year>
       2015
      </year>
      <volume>
       52
      </volume>
      <fpage>
       261
      </fpage>
      <lpage>
       271
      </lpage>
      <pub-id pub-id-type="pmid">
       25544738
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.psyneuen.2014.10.024
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bellavance
        </surname>
        <given-names>
         M-A
        </given-names>
       </name>
       <name>
        <surname>
         Rivest
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The HPA—Immune axis and the immunomodulatory actions of glucocorticoids in the brain
      </article-title>
      <source>
       Front. Immunol.
      </source>
      <year>
       2014
      </year>
      <volume>
       5
      </volume>
      <fpage>
       136
      </fpage>
      <pub-id pub-id-type="pmid">
       24744759
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3978367
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2014.00136
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="other">
      Klein, J.
      <italic>
       et al.
      </italic>
      Distinguishing features of Long COVID identified through immune profiling.
      <italic>
       medRxiv
      </italic>
      <ext-link ext-link-type="doi" xlink:href="10.1038/s41586-023-06651-y">
       https://doi.org/10.1038/s41586-023-06651-y
      </ext-link>
      (2023).
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Fischbach
        </surname>
        <given-names>
         G
        </given-names>
       </name>
      </person-group>
      <person-group person-group-type="editor">
       <name>
        <surname>
         Kandel
        </surname>
        <given-names>
         ER
        </given-names>
       </name>
       <name>
        <surname>
         Koester
        </surname>
        <given-names>
         JD
        </given-names>
       </name>
       <name>
        <surname>
         Mack
        </surname>
        <given-names>
         SH
        </given-names>
       </name>
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         SA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Synaptic transmission
      </article-title>
      <source>
       Principles of Neural Science
      </source>
      <year>
       2021
      </year>
      <publisher-name>
       McGrawHill
      </publisher-name>
      <fpage>
       241
      </fpage>
      <lpage>
       385
      </lpage>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hyman
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Tamminga
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <person-group person-group-type="editor">
       <name>
        <surname>
         Kandel
        </surname>
        <given-names>
         ER
        </given-names>
       </name>
       <name>
        <surname>
         Koester
        </surname>
        <given-names>
         JD
        </given-names>
       </name>
       <name>
        <surname>
         Mack
        </surname>
        <given-names>
         SH
        </given-names>
       </name>
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Disorders of mood and anxiety
      </article-title>
      <source>
       Principles of Neural Science
      </source>
      <year>
       2020
      </year>
      <publisher-name>
       The McGraw-Hill Company
      </publisher-name>
      <fpage>
       1515
      </fpage>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Camilleri
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Serotonergic modulation of visceral sensation: Lower gut
      </article-title>
      <source>
       Gut
      </source>
      <year>
       2002
      </year>
      <volume>
       51
      </volume>
      <fpage>
       i81
      </fpage>
      <lpage>
       i86
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD38XlslOjtLs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       12077074
      </pub-id>
      <pub-id pub-id-type="pmcid">
       1867727
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1136/gut.51.suppl_1.i81
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sjöstedt
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <name>
        <surname>
         Enander
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Isung
        </surname>
        <given-names>
         J
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Serotonin reuptake inhibitors and the gut microbiome: Significance of the gut microbiome in relation to mechanism of action, treatment response, side effects, and tachyphylaxis
      </article-title>
      <source>
       Front Psychiatry
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <fpage>
       682868
      </fpage>
      <pub-id pub-id-type="pmid">
       34122195
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8187765
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fpsyt.2021.682868
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         McCloskey
        </surname>
        <given-names>
         DJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Selective serotonin reuptake inhibitors: Measurement of effect on platelet function
      </article-title>
      <source>
       Transl. Res.
      </source>
      <year>
       2008
      </year>
      <volume>
       151
      </volume>
      <fpage>
       168
      </fpage>
      <lpage>
       172
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1cXitVentLc%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       18279816
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.trsl.2007.10.004
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kandel
        </surname>
        <given-names>
         ER
        </given-names>
       </name>
       <name>
        <surname>
         Koester
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Mack
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Siegelbaum
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <source>
       Principles of Neural Science
      </source>
      <year>
       2020
      </year>
      <publisher-name>
       The McGraw-Hill Companies
      </publisher-name>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mándi
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <name>
        <surname>
         Stone
        </surname>
        <given-names>
         TW
        </given-names>
       </name>
       <name>
        <surname>
         Guillemin
        </surname>
        <given-names>
         GJ
        </given-names>
       </name>
       <name>
        <surname>
         Vécsei
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Williams
        </surname>
        <given-names>
         RO
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Editorial: Multiple implications of the kynurenine pathway in inflammatory diseases: Diagnostic and therapeutic applications
      </article-title>
      <source>
       Front Immunol.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       860867
      </fpage>
      <pub-id pub-id-type="pmid">
       35251052
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8892578
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fimmu.2022.860867
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fanet
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Capuron
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <name>
        <surname>
         Castanon
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Calon
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Vancassel
        </surname>
        <given-names>
         S
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Tetrahydrobioterin (BH4) pathway: From metabolism to neuropsychiatry
      </article-title>
      <source>
       Curr. Neuropharmacol.
      </source>
      <year>
       2021
      </year>
      <volume>
       19
      </volume>
      <fpage>
       591
      </fpage>
      <lpage>
       609
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtFersrfI
      </pub-id>
      <pub-id pub-id-type="pmid">
       32744952
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8573752
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Guo
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection
      </article-title>
      <source>
       EBioMedicine
      </source>
      <year>
       2023
      </year>
      <volume>
       94
      </volume>
      <fpage>
       104729
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXhs1Gitr%2FI
      </pub-id>
      <pub-id pub-id-type="pmid">
       37506544
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10406961
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ebiom.2023.104729
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lim
        </surname>
        <given-names>
         CK
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2017
      </year>
      <volume>
       7
      </volume>
      <fpage>
       41473
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2017NatSR...741473L
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXit1Sgsbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       28155867
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5290739
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/srep41473
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="other">
      Cysique, L. A.
      <italic>
       et al.
      </italic>
      Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: A longitudinal observational study.
      <italic>
       medRxiv
      </italic>
      2022.06.07.22276020 (2022).
      <ext-link ext-link-type="doi" xlink:href="10.1101/2022.06.07.22276020">
       https://doi.org/10.1101/2022.06.07.22276020
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cron
        </surname>
        <given-names>
         RQ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Immunologic prediction of long COVID
      </article-title>
      <source>
       Nat. Immunol.
      </source>
      <year>
       2023
      </year>
      <volume>
       24
      </volume>
      <fpage>
       207
      </fpage>
      <lpage>
       208
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitFKqtLY%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36717724
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41590-022-01396-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chilosi
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Unbalanced IDO1/IDO2 endothelial expression and skewed keynurenine pathway in the pathogenesis of COVID-19 and Post-COVID-19 pneumonia
      </article-title>
      <source>
       Biomedicines
      </source>
      <year>
       2022
      </year>
      <volume>
       10
      </volume>
      <fpage>
       1332
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xhs12qsL3K
      </pub-id>
      <pub-id pub-id-type="pmid">
       35740354
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9220124
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/biomedicines10061332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kornhuber
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Hoertel
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Gulbins
        </surname>
        <given-names>
         E
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The acid sphingomyelinase/ceramide system in COVID-19
      </article-title>
      <source>
       Mol. Psychiatry
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       307
      </fpage>
      <lpage>
       314
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXit1WhsrfI
      </pub-id>
      <pub-id pub-id-type="pmid">
       34608263
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41380-021-01309-5
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Niitsu
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Iyo
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Hashimoto
        </surname>
        <given-names>
         K
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases
      </article-title>
      <source>
       Curr. Pharm. Des.
      </source>
      <year>
       2012
      </year>
      <volume>
       18
      </volume>
      <fpage>
       875
      </fpage>
      <lpage>
       883
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC38XlvVSqt7o%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       22288409
      </pub-id>
      <pub-id pub-id-type="doi">
       10.2174/138161212799436476
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Khani
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <name>
        <surname>
         Entezari-Maleki
        </surname>
        <given-names>
         T
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
      </article-title>
      <source>
       Mol. Psychiatry
      </source>
      <year>
       2022
      </year>
      <volume>
       27
      </volume>
      <fpage>
       3562
      </fpage>
      <lpage>
       3562
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XptlChsbo%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35388182
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8985056
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41380-022-01545-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bonnet
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <name>
        <surname>
         Juckel
        </surname>
        <given-names>
         G
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants—A scoping review
      </article-title>
      <source>
       J. Clin. Psychopharmacol.
      </source>
      <year>
       2022
      </year>
      <volume>
       42
      </volume>
      <fpage>
       284
      </fpage>
      <lpage>
       292
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xht1KksLbE
      </pub-id>
      <pub-id pub-id-type="pmid">
       35420565
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9042214
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1097/JCP.0000000000001543
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR37">
     <label>
      37.
     </label>
     <mixed-citation publication-type="other">
      Sidky, H.
      <italic>
       et al.
      </italic>
      Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19.
      <italic>
       medRxiv
      </italic>
      2022.11.09.22282142 (2023).
      <ext-link ext-link-type="doi" xlink:href="10.1101/2022.11.09.22282142">
       https://doi.org/10.1101/2022.11.09.22282142
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR38">
     <label>
      38.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mazza
        </surname>
        <given-names>
         MG
        </given-names>
       </name>
       <name>
        <surname>
         Zanardi
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Palladini
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Rovere-Querini
        </surname>
        <given-names>
         P
        </given-names>
       </name>
       <name>
        <surname>
         Benedetti
        </surname>
        <given-names>
         F
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
      </article-title>
      <source>
       Eur. Neuropsychopharmacol.
      </source>
      <year>
       2022
      </year>
      <volume>
       54
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       6
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitFGhtr7P
      </pub-id>
      <pub-id pub-id-type="pmid">
       34634679
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.euroneuro.2021.09.009
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR39">
     <label>
      39.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Banerjee
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <name>
        <surname>
         Robinson
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Sathian
        </surname>
        <given-names>
         B
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Treatment of Long COVID or Post COVID syndrome: A pharmacological approach
      </article-title>
      <source>
       Nepal J. Epidemiol.
      </source>
      <year>
       2022
      </year>
      <volume>
       12
      </volume>
      <fpage>
       1220
      </fpage>
      <lpage>
       1223
      </lpage>
      <pub-id pub-id-type="pmid">
       36407052
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9659683
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3126/nje.v12i3.48532
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR40">
     <label>
      40.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hersey
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Inflammation-induced histamine impairs the capacity of escitalopram to increase hippocampal extracellular serotonin
      </article-title>
      <source>
       J. Neurosci.
      </source>
      <year>
       2021
      </year>
      <volume>
       41
      </volume>
      <fpage>
       6564
      </fpage>
      <lpage>
       6577
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhvFOitbzJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       34083254
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8318079
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1523/JNEUROSCI.2618-20.2021
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR41">
     <label>
      41.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         di Filippo
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Low vitamin D levels are associated with long COVID syndrome in COVID-19 survivors
      </article-title>
      <source>
       J. Clin. Endocrinol. Metab.
      </source>
      <year>
       2023
      </year>
      <pub-id pub-id-type="doi">
       10.1210/clinem/dgad207
      </pub-id>
      <pub-id pub-id-type="pmid">
       37606222
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10505553
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR42">
     <label>
      42.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Barrea
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Vitamin D: A role also in long COVID-19?
      </article-title>
      <source>
       Nutrients
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       1625
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFeksLnI
      </pub-id>
      <pub-id pub-id-type="pmid">
       35458189
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9028162
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/nu14081625
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR43">
     <label>
      43.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Batista
        </surname>
        <given-names>
         KS
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The role of vitamin B12 in viral infections: A comprehensive review of its relationship with the muscle–gut–brain axis and implications for SARS-CoV-2 infection
      </article-title>
      <source>
       Nutr. Rev.
      </source>
      <year>
       2022
      </year>
      <volume>
       80
      </volume>
      <fpage>
       561
      </fpage>
      <lpage>
       578
      </lpage>
      <pub-id pub-id-type="pmid">
       34791425
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/nutrit/nuab092
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR44">
     <label>
      44.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Cella
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Chalder
        </surname>
        <given-names>
         T
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Measuring fatigue in clinical and community settings
      </article-title>
      <source>
       J. Psychosom Res.
      </source>
      <year>
       2010
      </year>
      <volume>
       69
      </volume>
      <fpage>
       17
      </fpage>
      <lpage>
       22
      </lpage>
      <pub-id pub-id-type="pmid">
       20630259
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.jpsychores.2009.10.007
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR45">
     <label>
      45.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bell
        </surname>
        <given-names>
         DS
        </given-names>
       </name>
      </person-group>
      <source>
       The Doctor’s Guide to Chronic Fatigue Syndrome: Understanding, Treating and Living with CFIDS
      </source>
      <year>
       1995
      </year>
      <publisher-name>
       Da Capo Lifepost Books
      </publisher-name>
     </mixed-citation>
    </ref>
    <ref id="CR46">
     <label>
      46.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Love
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       JASP: Graphical statistical software for common statistical designs
      </article-title>
      <source>
       J. Stat. Softw.
      </source>
      <year>
       2019
      </year>
      <volume>
       88
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       17
      </lpage>
      <pub-id pub-id-type="doi">
       10.18637/jss.v088.i02
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR47">
     <label>
      47.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wagenmakers
        </surname>
        <given-names>
         E-J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Bayesian inference for psychology. Part I: Theoretical advantages and practical ramifications
      </article-title>
      <source>
       Psychon. Bull. Rev
      </source>
      <year>
       2018
      </year>
      <volume>
       25
      </volume>
      <fpage>
       35
      </fpage>
      <lpage>
       57
      </lpage>
      <pub-id pub-id-type="pmid">
       28779455
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3758/s13423-017-1343-3
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR48">
     <label>
      48.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rouder
        </surname>
        <given-names>
         JN
        </given-names>
       </name>
       <name>
        <surname>
         Speckman
        </surname>
        <given-names>
         PL
        </given-names>
       </name>
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <name>
        <surname>
         Morey
        </surname>
        <given-names>
         RD
        </given-names>
       </name>
       <name>
        <surname>
         Iverson
        </surname>
        <given-names>
         G
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Bayesian t tests for accepting and rejecting the null hypothesis
      </article-title>
      <source>
       Psychon Bull. Rev.
      </source>
      <year>
       2009
      </year>
      <volume>
       16
      </volume>
      <fpage>
       225
      </fpage>
      <lpage>
       237
      </lpage>
      <pub-id pub-id-type="pmid">
       19293088
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3758/PBR.16.2.225
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR49">
     <label>
      49.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ballering
        </surname>
        <given-names>
         AV
        </given-names>
       </name>
       <name>
        <surname>
         Van Zon
        </surname>
        <given-names>
         SKR
        </given-names>
       </name>
       <name>
        <surname>
         Olde Hartman
        </surname>
        <given-names>
         TC
        </given-names>
       </name>
       <name>
        <surname>
         Rosmalen
        </surname>
        <given-names>
         JGM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Persistence of somatic symptoms after COVID-19 in the Netherlands: An observational cohort study
      </article-title>
      <source>
       Lancet
      </source>
      <year>
       2022
      </year>
      <volume>
       400
      </volume>
      <fpage>
       452
      </fpage>
      <lpage>
       461
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XitVGnsrbF
      </pub-id>
      <pub-id pub-id-type="pmid">
       35934007
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9352274
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S0140-6736(22)01214-4
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR50">
     <label>
      50.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Simone
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: A meta-analysis involving over 11,000 cases and 21,000 controls
      </article-title>
      <source>
       Eur. J. Epidemiol.
      </source>
      <year>
       2013
      </year>
      <volume>
       28
      </volume>
      <fpage>
       621
      </fpage>
      <lpage>
       647
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC3sXhsVOms73P
      </pub-id>
      <pub-id pub-id-type="pmid">
       23900608
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3935237
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s10654-013-9825-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR51">
     <label>
      51.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tran
        </surname>
        <given-names>
         VT
        </given-names>
       </name>
       <name>
        <surname>
         Porcher
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Pane
        </surname>
        <given-names>
         I
        </given-names>
       </name>
       <name>
        <surname>
         Ravaud
        </surname>
        <given-names>
         P
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <fpage>
       1812
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.1812T
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XptVelu7w%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35383197
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8983754
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-022-29513-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR52">
     <label>
      52.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Evers
        </surname>
        <given-names>
         AWM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Implications of placebo and nocebo effects for clinical practice: Expert consensus
      </article-title>
      <source>
       Psychother. Psychosom.
      </source>
      <year>
       2018
      </year>
      <volume>
       87
      </volume>
      <fpage>
       204
      </fpage>
      <lpage>
       210
      </lpage>
      <pub-id pub-id-type="pmid">
       29895014
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1159/000490354
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR53">
     <label>
      53.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Waber
        </surname>
        <given-names>
         RL
        </given-names>
       </name>
       <name>
        <surname>
         Shiv
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <name>
        <surname>
         Carmon
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <name>
        <surname>
         Ariely
        </surname>
        <given-names>
         D
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Commercial features of placebo and therapeutic efficacy
      </article-title>
      <source>
       JAMA
      </source>
      <year>
       2008
      </year>
      <volume>
       299
      </volume>
      <fpage>
       1016
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD1cXjtVSlsbs%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       18319411
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1001/jama.299.9.1016
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR54">
     <label>
      54.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sen
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Does serotonin deficiency lead to anosmia, ageusia, dysfunctional chemesthesis and increased severity of illness in COVID-19?
      </article-title>
      <source>
       Med. Hypotheses
      </source>
      <year>
       2021
      </year>
      <volume>
       153
      </volume>
      <fpage>
       110627
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtlyqtrrJ
      </pub-id>
      <pub-id pub-id-type="pmid">
       34139598
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8180092
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.mehy.2021.110627
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR55">
     <label>
      55.
     </label>
     <mixed-citation publication-type="other">
      Luiz Gonzaga Francisco de Assis Barros D’Elia, Z. The COVID-19 ‘Bad Tryp’ syndrome: NAD/NADH+, tryptophan phenylalanine metabolism and thermogenesis like hecatomb—The hypothesis of pathophysiology based on a compared COVID-19 and Yellow Fever Inflammatory Skeleton.
      <italic>
       J. Infect. Dis. Epidemiol.
      </italic>
      <bold>
       8
      </bold>
      (2022).
     </mixed-citation>
    </ref>
    <ref id="CR56">
     <label>
      56.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Matchkov
        </surname>
        <given-names>
         VV
        </given-names>
       </name>
       <name>
        <surname>
         Kravtsova
        </surname>
        <given-names>
         VV
        </given-names>
       </name>
       <name>
        <surname>
         Wiborg
        </surname>
        <given-names>
         O
        </given-names>
       </name>
       <name>
        <surname>
         Aalkjaer
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Bouzinova
        </surname>
        <given-names>
         EV
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Chronic selective serotonin reuptake inhibition modulates endothelial dysfunction and oxidative state in rat chronic mild stress model of depression
      </article-title>
      <source>
       Am. J. Physiol. Regul. Integr. Comp. Physiol.
      </source>
      <year>
       2015
      </year>
      <volume>
       309
      </volume>
      <fpage>
       R814
      </fpage>
      <lpage>
       R823
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28XoslCiur4%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       26269522
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1152/ajpregu.00337.2014
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR57">
     <label>
      57.
     </label>
     <mixed-citation publication-type="other">
      Farmacotherapeutisch Kompas.
      <ext-link ext-link-type="uri" xlink:href="https://www.farmacotherapeutischkompas.nl/">
       https://www.farmacotherapeutischkompas.nl/
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR58">
     <label>
      58.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Mariani
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Everson
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Pariante
        </surname>
        <given-names>
         CM
        </given-names>
       </name>
       <name>
        <surname>
         Borsini
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Modulation of microglial activation by antidepressants
      </article-title>
      <source>
       J. Psychopharmacol.
      </source>
      <year>
       2022
      </year>
      <volume>
       36
      </volume>
      <fpage>
       131
      </fpage>
      <lpage>
       150
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xjslehtrk%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       35098788
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8847767
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1177/02698811211069110
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR59">
     <label>
      59.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nguyen
        </surname>
        <given-names>
         NT
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis
      </article-title>
      <source>
       J. Exp. Pharmacol.
      </source>
      <year>
       2015
      </year>
      <volume>
       7
      </volume>
      <fpage>
       29
      </fpage>
      <lpage>
       35
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXmt1Gqtbw%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.2147/JEP.S63549
      </pub-id>
      <pub-id pub-id-type="pmid">
       27186143
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4863532
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR60">
     <label>
      60.
     </label>
     <mixed-citation publication-type="other">
      Mcgovern, K.
      <italic>
       et al.
      </italic>
      448 Discovery of clinical candidate IK-175, a selective orally active AHR antagonist. In
      <italic>
       Regular and Young Investigator Award Abstracts
      </italic>
      A272.1-A272 (BMJ Publishing Group Ltd, 2020).
      <ext-link ext-link-type="doi" xlink:href="10.1136/jitc-2020-SITC2020.0448">
       https://doi.org/10.1136/jitc-2020-SITC2020.0448
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR61">
     <label>
      61.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Rus
        </surname>
        <given-names>
         CP
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       A girl with self-harm treated with N-acetylcysteine (NAC)
      </article-title>
      <source>
       Tijdschr. Psychiatr.
      </source>
      <year>
       2017
      </year>
      <volume>
       59
      </volume>
      <fpage>
       181
      </fpage>
      <lpage>
       184
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1cvhvFSlsw%3D%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       28350146
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR62">
     <label>
      62.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Leitzke
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?
      </article-title>
      <source>
       Bioelectron. Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       9
      </volume>
      <fpage>
       2
      </fpage>
      <pub-id pub-id-type="pmid">
       36650574
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9845100
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1186/s42234-023-00104-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR63">
     <label>
      63.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhang
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Wen
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <name>
        <surname>
         Xiao
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       High-dose folic acid improves endothelial function by increasing tetrahydrobiopterin and decreasing homocysteine levels
      </article-title>
      <source>
       Mol. Med. Rep.
      </source>
      <year>
       2014
      </year>
      <volume>
       10
      </volume>
      <fpage>
       1609
      </fpage>
      <lpage>
       1613
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2cXhsVynsLnL
      </pub-id>
      <pub-id pub-id-type="pmid">
       24939255
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3892/mmr.2014.2332
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR64">
     <label>
      64.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tafet
        </surname>
        <given-names>
         GE
        </given-names>
       </name>
       <name>
        <surname>
         Nemeroff
        </surname>
        <given-names>
         CB
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Pharmacological treatment of anxiety disorders: The role of the HPA axis
      </article-title>
      <source>
       Front Psychiatry
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <fpage>
       443
      </fpage>
      <pub-id pub-id-type="pmid">
       32499732
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7243209
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3389/fpsyt.2020.00443
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR65">
     <label>
      65.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lebar
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Laganà
        </surname>
        <given-names>
         AS
        </given-names>
       </name>
       <name>
        <surname>
         Chiantera
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Kunič
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Lukanović
        </surname>
        <given-names>
         D
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The Effect of COVID-19 on the menstrual cycle: A systematic review
      </article-title>
      <source>
       J Clin Med
      </source>
      <year>
       2022
      </year>
      <volume>
       11
      </volume>
      <fpage>
       3800
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVSkur7M
      </pub-id>
      <pub-id pub-id-type="pmid">
       35807090
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9267255
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/jcm11133800
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR66">
     <label>
      66.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ferren
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2021
      </year>
      <volume>
       12
      </volume>
      <fpage>
       5809
      </fpage>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatCo..12.5809F
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitFKqt7nK
      </pub-id>
      <pub-id pub-id-type="pmid">
       34608167
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8490365
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-021-26096-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR67">
     <label>
      67.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Oberndorfer
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Saletu-Zyhlarz
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Saletu
        </surname>
        <given-names>
         B
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality
      </article-title>
      <source>
       Neuropsychobiology
      </source>
      <year>
       2000
      </year>
      <volume>
       42
      </volume>
      <fpage>
       69
      </fpage>
      <lpage>
       81
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3cXmsFOgsb0%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       10940762
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1159/000026676
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR68">
     <label>
      68.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Aarts
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Use of selective serotonin reuptake inhibitors and sleep quality: A population-based study
      </article-title>
      <source>
       J. Clin. Sleep Med.
      </source>
      <year>
       2016
      </year>
      <volume>
       12
      </volume>
      <fpage>
       989
      </fpage>
      <lpage>
       995
      </lpage>
      <pub-id pub-id-type="pmid">
       27092698
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4919000
      </pub-id>
      <pub-id pub-id-type="doi">
       10.5664/jcsm.5932
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR69">
     <label>
      69.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Panksepp
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Biven
        </surname>
        <given-names>
         L
        </given-names>
       </name>
      </person-group>
      <source>
       The Archaeology of Mind: Neuroevolutionary Origins of Human Emotions
      </source>
      <year>
       2012
      </year>
      <publisher-name>
       W. W. Norton &amp; Company
      </publisher-name>
     </mixed-citation>
    </ref>
    <ref id="CR70">
     <label>
      70.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Halpert
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <name>
        <surname>
         Amital
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <name>
        <surname>
         Shoenfeld
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Dysregulation of G protein-coupled receptors of the autonomic nervous system, adrenergic and muscarinic acetylcholine receptors, in patients with autoimmune dysautonomic-related disorders
      </article-title>
      <source>
       Brain Behav Immunol Health
      </source>
      <year>
       2020
      </year>
      <volume>
       4
      </volume>
      <fpage>
       100056
      </fpage>
      <pub-id pub-id-type="doi">
       10.1016/j.bbih.2020.100056
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR71">
     <label>
      71.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Medford
        </surname>
        <given-names>
         N
        </given-names>
       </name>
       <name>
        <surname>
         Sierra
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <name>
        <surname>
         Baker
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <name>
        <surname>
         David
        </surname>
        <given-names>
         AS
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Understanding and treating depersonalisation disorder
      </article-title>
      <source>
       Adv. Psychiatric Treat.
      </source>
      <year>
       2005
      </year>
      <volume>
       11
      </volume>
      <fpage>
       92
      </fpage>
      <lpage>
       100
      </lpage>
      <pub-id pub-id-type="doi">
       10.1192/apt.11.2.92
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR72">
     <label>
      72.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Simeon
        </surname>
        <given-names>
         D
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Depersonalisation disorder
      </article-title>
      <source>
       CNS Drugs
      </source>
      <year>
       2004
      </year>
      <volume>
       18
      </volume>
      <fpage>
       343
      </fpage>
      <lpage>
       354
      </lpage>
      <pub-id pub-id-type="pmid">
       15089102
      </pub-id>
      <pub-id pub-id-type="doi">
       10.2165/00023210-200418060-00002
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR73">
     <label>
      73.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sierra
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Depersonalization disorder: Pharmacological approaches
      </article-title>
      <source>
       Expert Rev. Neurother.
      </source>
      <year>
       2008
      </year>
      <volume>
       8
      </volume>
      <fpage>
       19
      </fpage>
      <lpage>
       26
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2sXhsVCgtb%2FL
      </pub-id>
      <pub-id pub-id-type="pmid">
       18088198
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1586/14737175.8.1.19
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR74">
     <label>
      74.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dale
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effects of serotonin in the hippocampus: How SSRIs and multimodal antidepressants might regulate pyramidal cell function
      </article-title>
      <source>
       CNS Spectr.
      </source>
      <year>
       2016
      </year>
      <volume>
       21
      </volume>
      <fpage>
       143
      </fpage>
      <lpage>
       161
      </lpage>
      <pub-id pub-id-type="pmid">
       26346726
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1017/S1092852915000425
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR75">
     <label>
      75.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nakhaee
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
      </article-title>
      <source>
       PLoS ONE
      </source>
      <year>
       2022
      </year>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0267423
      </pub-id>
      <pub-id pub-id-type="pmid">
       36201406
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9536564
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR76">
     <label>
      76.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dao
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A Systematic review on the potential of aspirin to reduce cardiovascular risk in schizophrenia
      </article-title>
      <source>
       Brain Sci.
      </source>
      <year>
       2023
      </year>
      <volume>
       13
      </volume>
      <fpage>
       368
      </fpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXltFKmt7s%3D
      </pub-id>
      <pub-id pub-id-type="pmid">
       36831911
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9954190
      </pub-id>
      <pub-id pub-id-type="doi">
       10.3390/brainsci13020368
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR77">
     <label>
      77.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lekakis
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules
      </article-title>
      <source>
       Int. J. Cardiol.
      </source>
      <year>
       2010
      </year>
      <volume>
       139
      </volume>
      <fpage>
       150
      </fpage>
      <lpage>
       158
      </lpage>
      <pub-id pub-id-type="pmid">
       19004511
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.ijcard.2008.10.010
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR78">
     <label>
      78.
     </label>
     <mixed-citation publication-type="other">
      Visser, D.
      <italic>
       et al.
      </italic>
      Long COVID is associated with extensive in-vivo neuroinflammation on [18 F]DPA-714 PET.
      <italic>
       medRxiv
      </italic>
      2022.06.02.22275916 (2022).
      <ext-link ext-link-type="doi" xlink:href="10.1101/2022.06.02.22275916">
       https://doi.org/10.1101/2022.06.02.22275916
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR79">
     <label>
      79.
     </label>
     <mixed-citation publication-type="other">
      Shen, W.-B.
      <italic>
       et al.
      </italic>
      SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology.
      <italic>
       bioRxiv
      </italic>
      2022.01.31.478476 (2022).
      <ext-link ext-link-type="doi" xlink:href="10.1101/2022.01.31.478476">
       https://doi.org/10.1101/2022.01.31.478476
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR80">
     <label>
      80.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hansen
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants
      </article-title>
      <source>
       Psychiatric Serv.
      </source>
      <year>
       2008
      </year>
      <volume>
       59
      </volume>
      <fpage>
       1121
      </fpage>
      <lpage>
       1130
      </lpage>
      <pub-id pub-id-type="doi">
       10.1176/ps.2008.59.10.1121
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <notes notes-type="Misc">
   <title>
    Tanbihi ya Mchapishaji
   </title>
   <p>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
